THE MICHAEL J. FOX FOUNDATION IS DEDICATED TO FINDING A CURE FOR PARKINSON’S DISEASE THROUGH AN AGGRESSIVELY FUNDED RESEARCH AGENDA AND TO ENSURING THE DEVELOPMENT OF IMPROVED THERAPIES FOR THOSE LIVING WITH PARKINSON’S TODAY.
Letter From the CEO, Founder and Co-Founder

Scientific Progress Report

High-priority Research Areas:
The Science We’re Most Excited About
Transforming Basic Discoveries Into Therapeutic Targets
Speeding Clinical Testing of New Interventions
Mobilizing New Technologies and Tools in PD Therapeutic Development

Select List of Organizations with Active MJFF Awards in 2009

Select List of 2009 MJFF Workshops and Summit Meetings

2009 in Photos

2009 Donor Listing

Financial Highlights
Letter from the CEO, Founder and Co-Founder

In 2009, with the support of more than 56,000 individuals, corporations and foundations, The Michael J. Fox Foundation continued to invest where we saw potential to drive progress forward, pushing ourselves and our partners to ever-greater heights in pursuit of transformative treatments and a cure for Parkinson's disease.

Against an uncertain economic backdrop, we funded over $39 million in targeted Parkinson’s research — the most we’ve ever funded in one year — bringing our total research investments at year-end to nearly $170 million. Yet those who know us know our core belief is that ending Parkinson’s is not merely about spending more money, but about spending that money with impact. Last year we expanded our emphasis on critical research tools and patients’ unmet needs while continuing to drive key next steps on top therapeutic targets. (Turn the page to read more about our high-priority research areas, the science we believe is closest or most critical to practical impact on patients’ lives.)

Sitting at the hub of global PD research, our job is to act urgently and strategically to dismantle roadblocks and streamline the path to a cure. We talk — and listen — to the world’s most prominent Parkinson’s scientists from academic and industry labs about what they need and where new opportunities lie. Our staff, which includes both scientific PhDs and business-trained project managers, continually surveys a wide and complex field in order to prioritize the projects most needed to accelerate new therapies. We work to see the big picture, then invest our capital with one return in mind: speeding scientific solutions to the nearly five million people living with Parkinson’s worldwide.

As Canada’s Globe and Mail reported in September, our aggressive, entrepreneurial approach to science lies at the heart of our mission to find a cure for Parkinson’s — and, in the process, to reshape the way medical research gets done. 2009 highlights include:

- Investing over $11 million in biomarker development (bringing total funding in this area to over $25 million) and laying the groundwork to sponsor the Parkinson’s Progression Markers Initiative (PPMI), a landmark biomarker study launching in 2010. (While PPMI isn’t covered in this report, you can learn more about it at michaeljfox.org/PPMI.)

- Allocating over $3 million to pre-clinical models, including a grant to speed a cutting-edge gene knockout technology into Parkinson’s therapeutic development within months of its advent. The technology was later named one of the top 10 scientific innovations of the year by The Scientist.

- Initiating a $1-million clinical trial to establish a framework for the development of effective treatments for dyskinesia, the debilitating side effect of long-term dopamine replacement therapy.

- With lead support from The Edmond J. Safra Foundation, awarding $2 million to drive development of treatment approaches for postural instability and gait disorder.
(PIGD), a troubling constellation of symptoms that are poorly understood and respond inconsistently or not at all to dopamine replacement therapies.

- With lead support from the Brin Wojcicki Foundation, executing an integrated, multi-million-dollar strategy to advance biological understanding of LRRK2, the single greatest known genetic contributor to Parkinson’s disease, while simultaneously laying the groundwork for effective LRRK2 clinical trials in the future.

- Launching PD Online Research (pdonlineresearch.org), a Web-based platform for research professionals to engage daily on key research hurdles and new findings. So far, nearly 2,000 Parkinson’s researchers at all levels and from all over the world have become members.

We invite you to read more about these investments, and the potential we see in them to change the face of Parkinson’s drug development, throughout this report and at michaeljfox.org.

Of course, effecting meaningful change in how new treatments are developed requires thoughtful strategies for engaging not only scientists but also patients and caregivers, policymakers and other research funders. That’s why in 2009 we also focused on building and deepening our relationships and collaborations in every sector of the PD community. We chartered a Patient Council to provide input on our programmatic activities from the critical perspective of those living with the disease. Our new Leadership Council is made up of generous advisors who provide leadership financial support and strategic insight about how we can more effectively engage new audiences to advance progress. And Team Fox, our grassroots fundraising network, continued to inspire and unite communities across the country in passionate pursuit of a cure.

Your dedication allows us to keep taking the risks that patients and their loved ones want taken in service of accelerating therapeutic breakthroughs. Our gratitude to you is as clear and strong as our vision of a world without PD.

Katie Hood  
CEO

Michael J. Fox  
Founder

Deborah W. Brooks  
Co-Founder
High-priority Research Areas: The Science We’re Most Excited About

While MJFF’s portfolio of investments includes up to 250 active grants spanning Parkinson’s therapeutic development, to achieve our mission of speeding the cure, we must strategically evaluate research hits and prioritize limited resources. This section provides an overview of our top priorities for funding and intellectual leadership. All are currently believed by our in-house research team and expert advisors to be critical areas of focus in our pursuit of transformative treatments for Parkinson’s in the shortest possible timeframe. You’ll find detailed stories about our work in these areas throughout this report.

Top Therapeutic Targets: Alpha-synuclein, LRRK2, Trophic Factors

Genetic targets Alpha-Synuclein and LRRK2. Though only a small fraction of people with Parkinson’s carry mutations in PD-implicated genes, findings from genetic studies open new avenues toward treatments that will benefit everyone with the disease. Two genetic targets, alpha-synuclein and LRRK2, have risen to prominence for their exceptional promise to provide new treatment approaches to Parkinson’s.

The gene known as alpha-synuclein produces a protein that aggregates to form Lewy bodies, microscopic clumps that are the pathological hallmark of PD. Though alpha-synuclein’s precise role in PD remains unclear, growing evidence supports the idea that decreasing its levels in the brain could be one way to slow or stop Parkinson’s progression. MJFF has invested more than $32 million in alpha-synuclein research to date.

First linked to PD in 2004, mutations in the LRRK2 gene are now believed to be the most common genetic contribution to the disease. MJFF is driving a comprehensive strategy for advancing LRRK2 research. The goal is to shed light on the gene’s biological role in PD while laying the groundwork for conclusive clinical trials. With lead support from The Brin Wojcicki Foundation, MJFF has invested over $16 million in LRRK2 research to date.

Trophic factors. Trophic factors (also known as neurotrophic factors or growth factors) are specialized proteins that protect and nurture neurons, including the dopamine neurons that die in Parkinson’s disease. While clinical trials involving trophic factors have not yielded hoped-for results, The Michael J. Fox Foundation continues to see great promise in trophic-based approaches to treating PD. The Foundation has invested over $20 million in trophic factor research to date, and in 2009 earmarked another $5 million under a 2010 LEAPS program to advance state-of-the-art trophic factor therapies into the clinic.
Patients’ Unmet Needs

Available treatments for Parkinson’s leave several troubling symptoms of the disease entirely unaddressed. These include cognitive deficits and mood disorders, problems with posture and gait, and gastrointestinal (GI) problems such as constipation. Complications of current treatments, including dyskinesia (the excessive, uncontrollable movements that result from long-term dopamine replacement therapy), also diminish quality of life.

The Michael J. Fox Foundation is committed to providing the financial and intellectual leadership required to drive treatments for patients’ unmet needs. Since its founding, MJFF has invested over $11 million in dyskinesia research, including a major clinical trial launched in December 2009 to validate vitally needed clinical scales (see page 15).

We have also funded millions of dollars in research toward alleviating untreated symptoms of PD — including developing the first pre-clinical models to mimic GI symptoms in Parkinson’s and, with lead support from The Edmond J. Safra Foundation, our 2009 $2-million initiative to drive treatments for postural instability and gait disturbances.

Critical Research Tools, New Technologies and Data Sharing

Pre-clinical models. With about $13 million in investments, MJFF is a field leader in the development of improved models of PD that accurately mimic the human condition, allowing researchers to test potential disease-modifying therapies. And to ensure that new and better models get into scientists’ hands as quickly and efficiently as possible, we also are developing practical, low-cost channels for worldwide distribution of these critical tools.

Biomarkers and clinical scales. To date we’ve invested nearly $29 million in biomarkers and clinical scales, tools necessary for researchers to definitively assess treatment effects in clinical studies. In 2009 we launched an initiative to validate clinical scales used to measure changes in dyskinesia severity. We also laid the groundwork to sponsor a game-changing longitudinal study, PPMI, launching in 2010, that will identify and verify PD biomarkers — molecular or physiological characteristics that can be objectively measured and evaluated to provide clearer outcomes from clinical trials and lower the hurdle to industry investment in PD.

Leveraging new technologies in PD. Research technologies emerge and evolve at a rapid pace. We monitor these developments and apply funding to strategically leverage those that could impact Parkinson’s science. In 2009 one such technology was named to The Scientist’s list of the top 10 scientific innovations of the year (see page 16).

Data sharing. New technologies and systems could revolutionize the way researchers communicate and share information. In addition to our ongoing activities to facilitate data exchange between and among academic and industry researchers, in 2009 we launched PD Online Research (PDOR) (www.pdonlineresearch.org). PDOR enables collaboration, instant communication and rapid problem-solving among scientists around the globe. Its goal is straightforward: enable quicker knowledge turns and faster progress toward therapeutic breakthroughs. By the end of the year, PD Online Research had almost 2,000 members from government, industry and academic sectors.
Transforming Basic Discoveries Into Therapeutic Targets

Basic discoveries about the biological mechanisms of Parkinson’s disease are critical to the development of new therapies. Equally important, however, is a focused and deliberate effort to shepherd these discoveries through the complex process of therapeutic development and determine their real potential as breakthrough treatments. The stories on these pages illustrate MJFF’s unique role in partnering with researchers to put the most promising results on a fast track toward practical relevance in patients’ lives.

Going Viral: Could a Virus’s RNA Help Protect Neurons?

Molecular virologist John Sinclair, PhD, of the University of Cambridge wasn’t even thinking about Parkinson’s when he discovered a previously unknown piece of viral RNA that keeps cells alive during infection. But his work on infectious disease elucidated an intriguing possibility: Could viral RNA protect the neurons that die in PD, thus modifying disease progression, something no current treatment has been proven to do?

MJFF quickly came on board to help him find out. With fast funding under MJFF’s Rapid Response Innovation Awards, Dr. Sinclair successfully engineered a form of the viral RNA suitable for pre-clinical testing, and his team demonstrated its ability to protect neurons in parkinsonian models. The Foundation then provided follow-on funding for Dr. Sinclair’s team to investigate the potential of the RNA complex to restore function to already-damaged neurons.

“PD patients have lost a substantial percentage of their dopaminergic neurons by the time of diagnosis,” says Dr. Sinclair. “So the real question is whether this complex can stop that process, preventing the disease from progressing further.” His group is also working to identify the specific region of the viral RNA responsible for the protective effects. “The more we can refine the RNA complex,” he explains, “the quicker we’ll be able to deliver a therapy from bench to bedside.”
“You don’t gain much by keeping things under wraps. Actually getting different people with different viewpoints and different techniques to work together in an open fashion rapidly speeds up progress.”

Patrick Lewis, University College London, MJFF LRRK2 Biology Consortium member

Sharing the Wealth (of Data): A Consortium Approach to Speed LRRK2-based Treatments

The LRRK2 gene holds tremendous promise as a therapeutic target for PD. Not only is it the single most common contributor to genetic cases of the disease, but it is a kinase — a type of cellular enzyme that is often highly druggable. Since LRRK2 was first linked to Parkinson’s disease in 2004, it has reinvigorated the field of Parkinson’s genetics and become the focus of intensive investigation by research teams all over the world.

MJFF’s research staff, in concert with the world’s leading experts in Parkinson’s genetics, has moved quickly to integrate global LRRK2 efforts into a united and streamlined scientific movement that will help minimize the timeline to practical LRRK2-based therapies. In 2009 MJFF homed in on collaborative efforts to increase understanding of LRRK2 biology, including convening a major LRRK2 summit at the end of the year. The spirit of collaboration was also extended to MJFF’s search for investigative teams to join a LRRK2 biology consortium aiming to fast-forward efforts to understand LRRK2 biology and target its vulnerabilities.

“This is a critical early moment in LRRK2 therapeutic development,” says Brian Fiske, PhD, associate director, team leader, Research Programs. “MJFF recognized the opportunity to transcend the disparate, one-off efforts that all too often characterize scientific discovery and instead lead a strategic new approach that hits on multiple fronts simultaneously.”

The journal *Nature Medicine* wrote: “To foster synergies moving forward, MJFF... established an international consortium to focus on one of the most promising candidate drug targets of the neurodegenerative disease. Under the terms of the two-year, $3.5-million grant design, members of the consortium, which includes both academic and industry partners, will be compelled to share results and collaborate with one another on an ongoing basis to help accelerate therapeutic discoveries.”

Nine different research teams are members of the LRRK2 biology consortium. They are working to help elucidate the functions of LRRK2 in the cell, identify other cellular proteins linked to LRRK2 (called substrates) and develop critical tools to drive further research. Several groups are using complementary approaches to investigate related questions around LRRK2. For example, three teams investigating substrates are using different types of tissues for each project, which will allow for faster and more efficient cross-validation of any findings.

“Getting people working together on LRRK2 research increases the pool of ideas and expertise to draw from, and it builds in a way to check your work with others, which is unfortunately rare in science,” says Mark Cookson, PhD, a member of the MJFF Scientific Advisory Board and world-renowned expert on the cell biology of PD. “It will also help to keep people involved in the field, pushing forward to the next level that much faster. It’s an approach grounded in common sense.”

---

**30** Number of labs funded by MJFF in 2009 that had never worked in PD before

**$6.6 million** Amount of 2009 research funded by MJFF in those labs
Leverage: MJFF’s Industry Strategy Bears Fruit

With over 55 currently active industry collaborations and more than 85 since MJFF’s inception, there is little doubt of the Foundation’s commitment to partnering with biotech and pharmaceutical companies to speed treatments toward clinical testing and patients. But the greater goal of the Foundation’s “de-risking” strategy is to create momentum and induce industry players to commit their own significant resources to pre-clinical and clinical Parkinson’s therapeutic development programs.

“We look for leverage everywhere,” says Debi Brooks, MJFF co-founder. “That means identifying the projects where it’s a good bet that our investment of, say, a few hundred thousand dollars can create a tipping point and increase the odds of a company investing millions down the line.”

Throughout 2009, mounting evidence suggested that MJFF has made several good bets on industry so far.

For example, Intra-Cellular Therapies, Inc. has been funded by the Foundation since 2006 to develop a small-molecule drug to increase the potency of levodopa, enabling relief of motor symptoms at lower doses and reducing dyskinesias. With positive outcomes in several relevant models of PD, principal investigator Gretchen Snyder, PhD, received supplemental funding in 2009 for what will likely be the final pre-clinical work required before a Phase 1 clinical trial.

Amicus Therapeutics of New Jersey also received MJFF funding in 2006 to test an orally administered small molecule with promise to decrease alpha-synuclein clumping, a hallmark of PD pathology. When the MJFF-funded test of a chaperone in a pre-clinical model of PD resulted in intriguing efficacy and dosing data, Amicus launched an internal PD drug development program. The company now expects to complete advanced pre-clinical proof-of-concept studies in Parkinson’s disease during the course of 2010 and to report additional data in the second half of the year.

“The support we received from The Michael J. Fox Foundation was a key factor in our decision to commit to a Parkinson’s program,” says John F. Crowley, chairman and CEO of Amicus. “In 2010 we expect to make significant progress in our pre-clinical programs in Parkinson’s disease.”

With funding from The Michael J. Fox Foundation, Intra-Cellular Therapies Inc (ITI) is developing therapeutics to promote the intracellular response of brain cells to dopamine and restore the functions of dopamine that are lost in Parkinson’s disease. In the schematic at right, dopamine, released from nerve terminals, interacts with receptor proteins to produce intracellular changes in second messengers and protein kinases that control the activity of brain cells through effects on different classes of proteins, including neurotransmitter receptors, ion pumps, ion channels and transcription factors. Based on the work of Paul Greengard, Nobel Laureate in Physiology & Medicine (2000).
G-CSF: A New Trophic Factor Approaches the Clinic

In 2006 researchers Mathias Baehr, MD, and Jochen Weishaupt, MD, of University Hospital Goettingen in Germany approached MJFF to discuss a growth factor called G-CSF (granulocyte-colony stimulating factor). G-CSF, already approved by the U.S. Food and Drug Administration to treat complications of chemotherapy in cancer patients, was believed to reduce cell death in a pre-clinical model of Parkinson’s disease. The researchers were awarded funding under MJFF’s Target Validation program to gather additional data critical for advancing to clinical trials in PD patients, such as an effective dose range.

In results published in the Journal of Neurochemistry and BMC Neuroscience, and presented at the Foundation’s third annual PD Therapeutics Conference in September 2009, the researchers conclusively demonstrated that G-CSF was protecting neurons in a PD model; they also shed light on how it was achieving this beneficial effect. The researchers then ran extensive pre-clinical studies on an enhanced form of G-CSF called pegfilgrastim, which minimizes side effects and remains in the system longer.

Within months, MJFF granted follow-on funding for final pre-clinical studies in another relevant Parkinson’s model. “We will monitor the effects of pegfilgrastim over time, look for any side effects and precisely measure its ability to reduce cell loss and improve motor symptoms in pre-clinical models,” says Dr. Weishaupt. “If all goes well, this will be the final step before a clinical study to test safety in Parkinson’s patients.”
Speeding Clinical Testing of New Interventions

MJFF shares patients’ urgency to bring new and better Parkinson’s therapies to market as fast as possible. In prioritizing clinical trials, we emphasize proof-of-principle and first-in-human studies that can alter the risk profile of a given treatment. We also help assemble and organize teams, lend expertise to biotech and pharmaceutical companies testing or going deeper into PD waters, vet the Parkinson’s potential of drugs approved for other diseases, and sponsor trials where intellectual property or patent issues reduce companies’ incentive to get involved.

How Sweet It Is: A Diabetes Drug that Could Modify Progression of PD

When reports of the anti-inflammatory properties of the diabetes drug pioglitazone began to surface in the early 2000s, scientists saw an opportunity to translate these findings into therapies for multiple diseases where inflammation is a contributing factor, including Parkinson’s disease. In 2002, this promising avenue of research was given a boost when pioglitazone was shown to prevent the death of dopamine neurons in pre-clinical models of PD.

In 2005, Marina Emborg, MD, PhD, director of the Preclinical Parkinson’s Research Program at the University of Wisconsin, received an MJFF Community Fast Track award to test the neuroprotective properties of orally administered pioglitazone in more relevant pre-clinical models of PD.

“We knew that pioglitazone might one day provide an innovative, simple and non-invasive strategy to prevent Parkinson’s progression,” says Dr. Emborg. “Furthermore, since pioglitazone is already known to be safe, it could be quickly translated into clinical trials in PD patients. MJFF funding was vital to our efforts to provide proof-of-principle for a new class of compounds to treat PD and other neurodegenerative disorders.”

When Dr. Emborg’s preliminary data suggested that the active compounds of pioglitazone were neuroprotective, MJFF provided supplemental funding to determine whether the doses used in pre-clinical models could be translated to humans. This work will provide critical data on optimal dosage to inform a clinical trial in PD patients slated to launch in 2010 with significant funding from NINDS, the National Institute of Neurodegenerative Disease and Stroke (NIH).

“Repurposing existing drugs for Parkinson’s could be a key approach to creating new and better treatment options for patients,” says Todd Sherer, “but it’s difficult for scientists to get funding for this kind of work. MJFF is committed to driving such efforts for the benefit of people living with the disease, and uniquely poised to do so.”
Wolfgang Oertel

Researchers and patients have long been intrigued by the link between tobacco and Parkinson’s disease. “There have been numerous compelling observations to suggest that tobacco exposure may hold multiple benefits for PD patients,” says Carlie Tanner, MD, one of the world’s leading experts on environmental factors in PD and a member of the MJFF Scientific Advisory Board. “Epidemiological studies consistently demonstrate that tobacco use lowers the risk of developing Parkinson’s disease, and experiments in pre-clinical models have shown that nicotine may protect dopaminergic cells from death. Several studies also suggest a symptomatic effect, though small and somewhat variable. And recent data shows that nicotine may reduce levodopa-induced dyskinesias.”

Yet key questions about the relationship among smoking, nicotine and Parkinson’s — including whether the protection seemingly conferred by smoking tobacco products stems from the nicotine in those products, other components of tobacco, or metabolic aspects related to smoking itself — remain unanswered.

In 2009 The Michael J. Fox Foundation awarded $1.1 million for NIC-PD, an international clinical trial vetting the effects of nicotine skin patches on Parkinson’s disease. It is the first long-term clinical trial expressly designed to test whether nicotine may in fact modify the progression of PD.

The double-blind, placebo-controlled trial — the first-ever multisite, investigator-initiated collaboration between Parkinson’s research groups in Germany and the United States — will be conducted over three years in 150 newly diagnosed Parkinson’s patients. (Study participants will be treated and observed for one year.) Principal investigators Wolfgang H. Oertel, MD, and Marcus M. Unger, MD, of Phillipps University Marburg, Germany, and Karl Kieburtz, MPH, of the University of Rochester, New York, will evaluate the disease-modifying potential of transdermal nicotine using standard nicotine skin patches of the type used by millions of smokers as a quitting aid.

Speaking to the journal CenterWatch Monthly, which reported on NIC-PD in its story “Michael J. Fox Foundation Gives German Investigator-initiated Trial New Life,” Dr. Oertel said: “I know a lot of foundations, and [MJFF is] amazingly well-organized, and they care. They really care what happens. They go to the advisory board meetings. [Usually,] the advisors meet without the scientists and then they are called in and either their head is chopped off or they get the check. But, at Michael J. Fox, you meet for two days with the advisors and they go with you through all the topics. It’s amazing. I’ve never experienced this before. It’s a unique situation. That is why they are so successful.”

“There’s no doubt that the epidemiological data on smoking and PD is intriguing,” says Katie Hood, CEO. “Our priority is on taking action to validate this data clinically in order to potentially translate it into a practical, patient-relevant therapy.”
Warning
An important cautionary note: While MJFF is funding clinical trials on supplements and drugs already available for purchase or prescription, people with Parkinson’s (other than those who ultimately enroll in these trials) should not begin taking these agents as part of a Parkinson's disease treatment regimen without the explicit recommendation of their doctor. Evidence to date has not yet definitively proved a benefit in PD, and these substances carry potential health risks, which doctors will carefully monitor in trial participants. It is crucial that all care and treatment decisions related to Parkinson’s disease and any other medical condition be made in consultation with a physician or other qualified medical professional.

Targeting Glutamate to Treat Levodopa-induced Dyskinesias

Developing effective treatments to alleviate dyskinesias — the disruptive, involuntary movements that are a side effect of long-term dopamine replacement therapy — is a high-priority research area for MJFF. In 2009 one promising approach involving glutamate — a neurotransmitter of increasing interest to PD researchers — moved forward to the early stages of clinical research. MJFF has been a champion of an approach targeting a specific glutamate receptor, mGluR5, since 2005. The Foundation’s de-risking efforts have now chaperoned mGluR5 from basic discovery to clinical testing and attracted industry interest in the target.

“Finding new and safe treatments that can prevent dyskinesias would allow patients to continue on levodopa, benefiting from its full symptomatic efficacy even in advanced stages of the disease,” says Todd Sherer, PhD, vice president, Research Programs. “This would lead to an enormous improvement in patients’ quality of life.”

The initial data on mGluR5 and dyskinesia came from Angela Cenci-Nilsson, MD, PhD, of Lund University in Sweden. In 2005 Dr. Cenci-Nilsson received a Target Validation award to demonstrate that blocking the action of one particular receptor, mGluR5, prevented levodopa-induced dyskinesias in rodent models of PD.

The Foundation quickly provided follow-on funding for Dr. Cenci-Nilsson to partner with Erwan Bezard, PhD, of the University of Bordeaux in France. Their goal: take preliminary results to the next level in a more relevant model of PD. The pair worked closely with MJFF research staff to identify a compound capable of reducing mGluR5 activity. Finding one already in human clinical testing for another disease, they adapted their studies to this compound to accelerate development toward the clinic.

Abnormal involuntary movement scores, a measure of dyskinesia severity, increase over time in parkinsonian models treated with levodopa (represented by red squares). This increase is blunted in models receiving treatment with an mGluR5 antagonist as an add-on to levodopa (represented by blue triangles). The mGluR5 antagonist alone does not induce any abnormal involuntary movements (represented by yellow circles). Each data point represents the average value from eight to 10 models in each group.
MJFF is now partnering with Danna Jennings, MD, of The Institute for Neurodegenerative Disorders in New Haven, Connecticut, to verify the action of this compound and determine a safe and effective dose for use in future clinical trials. Using PET scans and a fluorescent imaging molecule that binds to mGluR5, Dr. Jennings images PD patients’ brains before and after treatment. “An important step before investing in a large clinical trial is to make sure that the drug is in fact getting to the brain and binding to the expected targets,” says Dr. Jennings. “Is the drug reaching the brain at appropriate levels? What is the dose most likely to provide meaningful clinical benefit? Our research aims to answer these questions.”

MJFF’s commitment has galvanized the field, prompting industry scientists to conduct clinical testing of other compounds targeting mGluR5. “By driving pre-clinical development of promising drug targets, MJFF is providing tangible incentives for industry to increase its involvement in Parkinson’s research,” concludes Dr. Sherer. “The development of dyskinesia therapies based on mGluR5 activity is a perfect example of this strategy.”

---

**UPDATE**

**Serotonin and Dyskinesia: MJFF Support Leads to Pilot Clinical Trial**

*Progress 2008 featured the efforts of Anders Björklund, PhD, and his colleague, Manolo Carta, PhD, of Lund University in Sweden to develop a new treatment for dyskinesia targeting the brain’s serotonin system, better known for its role in clinical depression. With Foundation funding, the researchers have now demonstrated that abnormal, dyskinesia-inducing dopamine release can be effectively blocked by drugs that act on two specific receptors, known as 5-HT1A and 5-HT1B, located on the serotonin neurons. They have also shown that this technique is particularly effective when the two receptors are activated simultaneously.*

*Based on these results, Dr. Björklund’s team is now conducting an MJFF-funded pilot clinical trial in 24 Parkinson’s patients at Lund University Hospital and Karolinska Hospital Huddinge (both in Sweden). The trial is being carried out in collaboration with the U.S. biotech company PsychoGenics, using their proprietary drug Eltoprazine, which activates both 5-HT1A and 5-HT1B and has shown promising results in pre-clinical trials to date.*

---

**Structure of the neurotransmitter serotonin**

---

“The Michael J. Fox Foundation’s staff are highly committed, truly capable people. They monitor your progress; they’re extremely aware of where Parkinson’s research is going and where it needs to go. They won’t fund a project just because it’s trendy, or because of a scientist’s famous name. Their goal is to promote quality research with high translational value, and they do everything to achieve that goal.”

Angela Cenci-Nilsson

---

$10.1 million

Amount of research funded by MJFF in 2009 to address patients’ unmet needs including dyskinesia
Mobilizing New Technologies and Tools in PD Therapeutic Development

To advance therapeutic targets toward the clinic requires highly specialized tools and technologies, whose development in itself requires significant financial and intellectual investment. But there is no financial incentive for any single stakeholder to allocate major funding to this critical need. MJFF, with its singular focus on patient-relevant outcomes, is uniquely positioned to marshal the resources and partners that can propel development of tools and technologies with potential to move the entire field forward.

Using Virtual Reality to Address Freezing of Gait

An MJFF-funded team in Sydney, Australia, is using functional magnetic resonance imaging (fMRI) in a virtual environment to visualize patients’ brains while safely triggering freezing of gait episodes. The project is part of a $2-million MJFF commitment to therapeutic development for postural instability and gait disturbances in Parkinson’s disease, made possible with lead funding from The Edmond J. Safra Foundation.

While lying in the MRI scanner, patients will use foot pedals to ‘walk’ through a realistic three-dimensional environment they see on a small screen. The virtual environment task will probe cognitive processes that often provoke freezing episodes (such as sliding doors) or alleviate them (such as striped floors).

“We hypothesize that rather than simply reflecting a process related to gait, freezing episodes are in fact related to a breakdown in the circuitry that coordinates different functions such as movement and thinking,” says principal investigator Simon Lewis, MD. “We want to identify the abnormal pattern of brain activation — hopefully increasing understanding of freezing and opening new directions for targeting therapy.”

“Throughout all my experiences with MJFF I’ve been impressed with the rigor and accountability of the Foundation’s process, and with the creative and competent way that the staff goes about its mission of finding better treatments and a cure for Parkinson’s disease. I’m willing to dedicate as much time and effort to the Foundation as I do because I truly believe this organization is going to make a difference.”

Gene Johnson, PhD, Chief Scientific Advisor, MJFF
Maximizing Learning from At-risk Populations: MJFF Drives LRRK2 Cohort Studies in New York, Tel Aviv and Tunisia

On page 7 you read about the LRRK2 biology consortium, part of MJFF’s strategy to increase understanding of the LRRK2 gene that is believed to be the single most common contributor to genetic cases of Parkinson’s disease. The Foundation is simultaneously working to define the clinical impact of LRRK2 on PD — that is, how LRRK2 may cause or prevent specific symptoms, impact rate of progression, or otherwise affect disease severity and trajectory.

The Foundation is funding two research teams to study PD in cohorts of Ashkenazi Jews and North African Arab-Berbers, two populations with a significantly elevated incidence of the PD-implicated LRRK2 mutation known as G2019S. What they learn will not only provide answers about what it means to have a LRRK2 mutation, but also open new avenues of therapeutic development for people with the far more common sporadic form of the disease.

A team of investigators from Mayo Clinic, Jacksonville, and the Institute of Neurology in Tunis is following an Arab-Berber cohort in Tunisia. A second group comprising investigators at Beth Israel Medical Center, Columbia University, Tel Aviv Sourasky Medical Center and the Institute for Neurodegenerative Disorders is tracking Ashkenazi Jews in New York and in Tel Aviv, Israel.

“Not all people with LRRK2 mutations get PD, and for those who do develop the disease, there is great variability in symptoms,” says Susan Bressman, MD, of Beth Israel Medical Center, coordinating principal investigator for the New York/Tel Aviv cohort. “By studying large numbers of people with the same mutation, we can start to understand its implications for risk and disease course in individuals.”

To ensure that all data collected can be analyzed, shared and compared as efficiently and meaningfully as possible, MJFF worked with the investigators to set up collection methods standardized across both cohorts. This will improve the ability of the researchers to compare results and link clinical features to underlying biological and genetic processes.

“It’s by studying these uniquely affected populations, our goal is to make drug development efforts centered on LRRK2 more efficient and ultimately speed patient-relevant outcomes from this work,” says Katie Hood, CEO.

A Critical Step toward Controlling Dyskinesia

The drug levodopa is the gold-standard treatment for relieving the stiffness, tremors and rigidity of PD. But patients are forced to weigh symptomatic relief against the knowledge that, at some point, levodopa will very likely cause dyskinesia. Patients wait as long as possible to begin levodopa; even after starting, many limit dosage to reduce the risk of dyskinesia. If dyskinesia develops, patients often reduce their levodopa dose and settle for a lesser benefit from the best medical therapy available for their disease.

Dyskinesia is a moving target in every sense of the phrase. It takes different forms and varies widely from day to day and even hour to hour. Partly for this reason, the development of accurate clinical scales to detect type, severity, duration, and impact on the patient has been elusive. While several scales exist, their effectiveness has never been rigorously compared. Without scales the scientific community has confidence in, there is no framework for clinical testing of possible new treatments. This in turn creates a hurdle to biotech and pharmaceutical companies investing in the development of potential new dyskinesia therapies.

In 2009, as part of its ongoing efforts to drive new dyskinesia treatments, The Michael J. Fox Foundation announced a $1-million clinical study to validate effective dyskinesia scales. The multi-site study, led by Christopher Goetz, MD, at Rush University Medical Center in Chicago, will aim to conclusively identify the scales that most accurately measure dyskinesia.

The experimental design involves amantadine, a current, albeit inadequate, drug frequently used off-label to treat dyskinesia. Patients will be treated with amantadine or placebo, and then have their dyskinesia rated over the course of several weeks using numerous dyskinesia measurement scales. (The researchers will examine the response to placebo as well, in order to favor scales that maximally separate placebo-associated changes from amantadine-associated changes.) The results will establish a path for clinical testing of future promising novel dyskinesia treatments, increasing the likelihood of industry investment in future clinical trials.
Model Techniques for Speeding PD Drug Development

Pre-clinical models are vital tools for drug development. Researchers require good models to increase understanding of cellular, molecular and behavioral aspects of disease, as well as to screen potential new therapies before they move forward to testing in humans. Parkinson’s therapeutic development is held back by the lack of any pre-clinical model that accurately recapitulates both the underlying processes, and the symptoms, of the human condition. Even when good models are developed, better distribution channels are required to quickly get them into researchers’ hands.

Knocking out PD

A laboratory technique known as gene knockout lets scientists working in pre-clinical models remove a specific gene of interest, effectively turning it off (“knocking it out”), allowing them to study genes’ effects on cellular disease processes. Gene knockout has been used for decades in laboratory mice, but never successfully in rats until July 2009, when biotech Sigma-Aldrich published proof-of-principle for the first knockout rats.

“Rats offer numerous advantages as models for Parkinson’s drug development,” says Todd Sherer, PhD, vice president, Research Programs. “They more closely mimic many behavioral aspects of human Parkinson’s disease, offer a greater amount and wider range of tissue for testing and allow scientists to conduct certain tests that are impossible in mice or non-mammalian models.”

Sigma-Aldrich used a novel technology called Zinc Finger Nuclease (ZFN). It causes targeted breaks in double-stranded DNA that can snip out specific genes of interest. ZFN was developed by Sangamo BioSciences and licensed to Sigma-Aldrich in 2007. Its application in rats would later be named one of the top 10 scientific innovations of 2009 by The Scientist.

By August MJFF had awarded a Sigma-Aldrich team led by Edward Weinstein, PhD, a one-year grant to develop five Parkinson’s knockout models, each lacking one gene known to play a role in PD: alpha-synuclein, LRRK2, DJ-1, Parkin and PINK1. The creation of knockout rat models of PD will provide new opportunities for understanding the functions of different PD-implicated genes. The researchers expect to report back to MJFF on the creation and characterization of their models by mid-2010.

A pre-clinical model shows the effects of a human LRRK2 mutation

In 2009, with funding from MJFF under the Development of Progressive Pre-clinical Models of PD initiative, CJ Li, PhD, of Weill Cornell Medical College published the first reported mouse model for the study of LRRK2 gene mutations. (Read more about LRRK2 on page 4). Unlike the knockout rats, Dr. Li’s mouse models express the human LRRK2 gene, allowing scientists for the first time to evaluate the progressive effects of these gene mutations — a critical step in the process of converting genetic discoveries into patient-relevant therapies and a vital need for biotech and pharmaceutical companies working to develop new treatments for Parkinson’s.

“Dr. Li’s models represent a much-needed pre-clinical tool to screen and validate potential new therapies for Parkinson’s disease,” says
MJFF Scientific Advisory Board member Kalpana Merchant, PhD, of Eli Lilly and Co. “They also can be used to study the underlying mechanisms of LRRK2 mutations and how they contribute to PD.”

MJFF has quickly provided supplemental funding to Dr. Li and collaborator J. Timothy Greenamyre, MD, PhD, of the University of Pittsburgh to further characterize neurobehavioral deficits, neurochemical irregularities, dopamine cell loss, neuropathology, and molecular features in models of different ages.

“We anticipate that these models of PD will recapitulate various components of the human disease,” says Dr. Li. “This increases the potential that meaningful comparisons can be made between what we find in the models and what is seen in PD patients.”

Practical distribution channels for widespread access to the best tools

To reduce the costs and improve the speed and efficiency of producing and distributing research models, in 2009 MJFF partnered with The Jackson Laboratory (JAX) in Bar Harbor, Maine, to strengthen JAX’s existing Parkinson’s Disease Mouse Model Repository. The repository will house and distribute valuable MJFF-funded mouse models for use by the entire PD research community, removing a significant barrier to access. The mouse models created by Dr. Li and his colleagues, as well as other pre-clinical models developed with funding from MJFF, are already at JAX and ready for distribution.

“Working with JAX is one example of how MJFF is doing whatever it takes to speed drug development by getting the best research tools into as many scientists’ hands as possible,” says Sohini Chowdhury, associate director, team leader, Research Programs. “We can’t stand by and watch access issues slow down research progress.”
Our Global Reach: Select List of Organizations with Active MJFF Awards in 2009

With up to 250 active awards in our portfolio at any given time, The Michael J. Fox Foundation is continuously engaging with Parkinson’s disease researchers and thought leaders across the globe. Below are the organizations, companies and institutes that initiated new MJFF-funded PD research projects in 2009.

**United States**
- Acadia Pharmaceuticals
- Adolor Corporation
- Alzheimer Research Forum
- Amylin Pharmaceuticals, Inc.
- ArmaGen Technologies, Inc.
- Beth Israel Deaconess Medical Center
- Bodey, LLC
- Brandeis University
- Brigham & Women's Hospital
- Brown University
- Caliper Life Sciences (Xenogen)
- Carmot Therapeutics, Inc.
- Case Western Reserve University
- Ceregene, Inc.
- Chaperone Therapeutics, Inc.
- Codman and Shurtleff, Inc.
- Colorado State University
- Columbia University
- Coriell Institute for Medical Research
- Covance
- Creative Commons
- Duke University
- Emory University
- Envivo Pharmaceuticals
- Epitomics
- FoldRx Pharmaceuticals, Inc.
- Foundation for the National Institutes of Health
- Harvard University
- Henry Ford Health System
- In Silico Biosciences
- Indiana University
- Intra-Cellular Therapies, Inc.
- Invitrogen Corporation
- Isis Pharmaceuticals, Inc.
- Life Technologies
- Louisiana State University Health Sciences Center-Shreveport
- Massachusetts General Hospital
- Mayo Clinic
- Medtronic Neuromodulation
- Montana State University
- Mount Sinai School of Medicine
- National Institute on Aging (NIA)/NIH
- Northern California Institute for Research & Education
- Northwestern University
- Oregon Health & Science University
- Parexel
- Pfizer Global Research and Development
- Purdue University
- Retrotepe, Inc.
- Rockefeller University
- Rush University
- Saint Jude Children’s Research Hospital
- Satoris, Inc.
- Sigma-Aldrich
- Sign Path Pharma, Inc.
- SRI International
- Stanford University
- Sun Health Research Institute
- Targacept, Inc.
- The Burnham Institute for Medical Research
- The Institute for Neurodegenerative Disorders
- The Jackson Laboratory
- The Parkinson's Institute
- The Salk Institute for Biological Studies
- Thomas Jefferson University
- University of Alabama at Birmingham
- University of California, Los Angeles
- University of California, San Francisco
- University of Chicago
- University of Cincinnati
- University of Colorado at Denver & Health Sciences Center
- University of Colorado Denver
- University of Florida
- University of Illinois at Chicago
- University of Iowa
- University of Pennsylvania
- University of Pittsburgh
- University of Rochester
- University of South Florida
- University of Southern California
- University of Texas
- University of Texas Southwestern Medical Center at Dallas
- University of Washington
- Virginia College of Osteopathic Medicine
- Wayne State University
- Weill Medical College
- Australia
- University of Sydney
- University of Melbourne
- Austria
- University of Innsbruck
- Belgium
- University of Liege
- Katholieke Universiteit Leuven
- reMYND NV
- Canada
- University of Alberta
- University of Ottawa
- NeurAxon, Inc.
- Toronto Western Hospital
- Neurodyn Inc.
- Denmark
- University of Aarhus
- France
- University of Bordeaux
- University of Nantes
- INSERM
- Toulouse University Hospital
- Germany
- InterMed Discovery GmbH
- Max Planck Institute for Biophysical Chemistry
- NextPharma
- University Hospital Goettingen
- Philipps University Marburg
- Greece
- Foundation for Biomedical Research of the Academy of Athens
- Ireland
- Opsona Therapeutics LTD
- Israel
- Hebrew University-Hadassah Medical School
- Tel Avir Sourasky Medical Center
- Italy
- University of Brescia
- University of Padova
- Spain
- Universidad Autonoma de Madrid
- Sweden
- Lund University
- Switzerland
- Swiss Federal Institute of Technology Lausanne
- Tunisia
- National Institute of Neurology
- United Kingdom
- PRN
- University of Dundee
- University of Cambridge
- GlaxoSmithKline
- Imperial College London
- Institute of Neurology
- University of Newcastle upon Tyne

761 Number of grant applications reviewed by MJFF in 2009
Our Power to Convene: Select List of 2009 MJFF Workshops and Summit Meetings

In 2009, MJFF brought together more than 500 top researchers from academic and industry labs all over the world for approximately 40 conferences, summit meetings and workshops. These sessions catalyzed concrete action steps — new grant programs, funding for critical tools and resources, novel collaborations and other tactical interventions to move the best ideas forward faster.

**ADDF Drug Discovery for Neurodegeneration, February 2–3**
*(Sponsored by the Alzheimer’s Drug Development Foundation)*

Tod Sherer, PhD, vice president Research Programs, chaired a session on drug discovery and development for neurodegenerative diseases. Participants brainstormed potential solutions to issues including selection of research models, target validation and pre-clinical development.

**Placebo Response Workshop, March 30**
*(Co-funded by The Davis Phinney Foundation)*

Leading experts prioritized strategies for gaining a greater understanding of placebo effects in Parkinson’s to improve the design and testing of future therapeutics. The placebo effect — in which patients who receive an inert substance nonetheless experience some or all benefits of active treatment — has increasingly complicated the interpretation of outcomes from PD clinical trials, creating a significant hurdle to the development of new treatments.

**Next Steps on Dyskinesia, June 3**

World-leading experts on dyskinesia, including members of the Foundation’s Dyskinesia Working Group, assessed the status of various therapeutic approaches to alleviating this debilitating complication of long-term dopamine replacement therapy, and prioritized strategic next steps for MJFF and the field.

**Third Annual PD Therapeutics Conference, September 30**

Nearly 200 academic and industry researchers and business development professionals attended the only major scientific symposium exclusively focused on speeding PD therapeutic development.

**Industry Strategy Session, October 8**

Global leaders of biotech and pharmaceutical firms provided crucial feedback on MJFF’s efforts to engage industry to date. Participants also suggested next steps on de-risking Parkinson’s drug targets and explored additional ways that the Foundation could partner with industry to speed the development of transformative treatments and a cure for PD.

**Partnering for Cures, December 1–3**
*(Sponsored by FasterCures)*

Katie Hood, CEO, Debi Brooks, co-founder, and senior MJFF staff members participated in this first-of-its-kind meeting that brought together philanthropies, medical research foundations, and the biopharmaceutical industry in an effort to forge strategic collaborations key to the timely development of new medical treatments.

**LRRK2 Summit, December 9**

Global experts in PD genetics assessed the state of the field in LRRK2 biology and therapeutic development, evaluated MJFF and field-wide activities, and recommended actions for MJFF and the field to accelerate understanding of the role of LRRK2 and its translation into meaningful therapies for people with Parkinson’s disease.
2009 in Photos

1. Julianne Moore and Bart Freundlich.
2. Gregg Allman, Denis Leary, Sam Fox, Elvis Costello, Roger Daltry, Michael J. Fox, John Popper and Steven Tyler backstage at “A Funny Thing Happened on the Way to Cure Parkinson’s Disease.”
3. Board member David Einhorn and his wife, Cheryl.
4. Amar Kuchinad, the top Team Fox fundraiser of 2009, after the NYC Half Marathon.
5. Board member Ryan Reynolds.
6. Twins Drew and Kyle Shackleton run the Chicago Marathon for Team Fox, qualifying for the Olympic trials in the process.
7. Michael J. Fox and Stevie Wonder at “A Sunny Thing Happened on the Way to Cure Parkinson’s Disease.”
8. Allison Maguire and Brian Grant (formerly of the Portland Trailblazers).
10. MJFF Board Chair George Prescott and his daughter, Cheri.

11. Board member Al Glickman with his wife, Judy, and Michael J. Fox.


14. Tracy Pollan and Michael J. Fox.

15. Michael J. Fox, Martin and Helen Scorsese and Ronald O. Perelman.

16. Scott Fahey, Board member Doug Ostrover, MJFF CEO Katie Hood, Scott Williams and Board member Curtis Schenker.
In 2009, with the help of more than 56,000 individuals, corporations and foundations, The Michael J. Fox Foundation funded over $39 million in Parkinson’s research. We are deeply grateful for our donors’ ongoing commitment to our mission to discover breakthrough treatments for Parkinson’s disease.

This report lists those who honored us with significant contributions last year. Also listed are the many friends and family members to whom they paid tribute with their donations. It is in their name and spirit that we work with continued urgency toward a cure.

**2009 Donor Listing**

- **$25,000,000 or more**
  - The Brin Wojcicki Foundation

- **$10,000,000 or more**
  - Chris Sullivan*

- **$2,000,000 or more**
  - EMD Serono*
  - Kinetics Foundation*
  - Judith and George Prescott and Family*
  - The Edmond J. Safra Foundation*
  - The Dotha S. Welbourn Charities Trust

- **$1,000,000 or more**
  - Margaret C. Glosser Trust
  - Judy and Al Glickman/Albert Glickman Family Foundation
  - Anne and Burt Kaplan*
  - Shackleton Family*

- **$500,000 or more**
  - Benaroya Foundation
  - Donny Deutsch*
  - Elan Pharmaceuticals, Inc.*
  - Great Investors’ Best Ideas Foundation/Michele and Shad Rowe

*recognizes multi-year commitment
$250,000 or more
Estate of Sam M. Anderson
Cheryl and David Einhorn
Lisa Piazza and David Golub*
Greenlight Capital, Inc.
Shannon and Mark L. Hart III
Estate of John Christopher Kimsey
Lazard Capital Markets
Jean Patton 2005 Revocable Trust
Carolyn and Curtis Schenker
Karen Pritzker and Michael Vlock

$100,000 or more
Anonymous (2)
Estate of Helen Bennett
Shanna and Jon Brooks
Virginia Brooks*
BTIG, LLC
The James E. Cayne and Patricia D. Cayne Charitable Trust
Joyce and Barry Cohen
J. & F. Coody Inter Vivos Trust
Cantor Fitzgerald
Trace Pollan and Michael J. Fox
The Sol and Lillian Goldman Family
Karen Finerman and Lawrence Golub
John and Amy Griffin Foundation
The Leona M. and Harry B. Helmsley Charitable Trust
Holly Andersen, MD, and Douglas Hirsch*
Rachel and Amar Kuchinad
Dorothea L. Lesher Estate
Allison and Casey Maguire
Julie and Doug Ostrow
Parkinson’s Unity Walk
Ronald O. Perelman
Parkinson’s Unity Walk
Julie and Doug Ostrover
Allison and Casey Maguire
Julie and Doug Ostrow
Parkinson’s Unity Walk
Ronald O. Perelman
Robert Pritzker
The Pumpkin Foundation/Joe and Carol Reich
Mrs. Edmond J. Safra
Carl and Ruth Shapiro Family Foundation

$50,000 or more
Anonymous (3)
Bachmann-Strass Dystonia and Parkinson Foundation, Inc.
Sara and Kate Bloom Fund
Boehringer Ingelheim Pharmaceuticals, Inc.
Claire and Jason Capello
Barbara and Julian Cherubini
Estate of Beryl Deming
French American Charitable Trust
The Greater Kansas City Community Foundation & Affiliated Trust
Carolyn and Edwin Levy
Jennifer and Marc Lipschultz
Joella and John Lykouretzos
The Mann Family Foundation
Zella M. McClure
The Miller Family Foundation
Edna May Minnick Estate
Newman’s Own Foundation, Inc.
Oak Creek Foundation
Pershing Square Capital Management
Prince Charitable Trusts
Caroleen Fenney and Richie Rotenberg
Salvay Pharmaceuticals
Katherine Farley and Jerry L. Speyer

$25,000 or more
Anonymous
The Jeffrey A. Altman Foundation
Bloomberg
Julie Bowen and Scott Phillips
Estate of Ruth Carter
Ellen Hooker and Joseph Cassano
Morgan Management — Robert Morgan, Robert Moser, Chase Chavin and their families
Sonya and Dev Chodry
Stuart Clifton
Steven and Alexandra Cohen Foundation
Camille and Michael Costa
DEARS Foundation, Inc.
Deutsche Bank Securities, Inc.
Dillard’s, Inc.
Jane and Rudolph DiNunzio
Norma Doering*
Eva Andersson-Dubin, MD, and Glenn Dubin
Valerie Feigen and Steven Eisman
Richard H. Fitzgerald
Lee Fixel
Jay Goldman
Susan and Kim Henry
Buddy and Edna Herring
Armin & Esther Hirsch Foundation
Marjorie and Robert Hirschhorn
Ionic Capital Management
Sonia and Paul T. Jones
The Kellar Family Foundation
The Lauder Foundation
Douglas Liebhaber and Wendy Gimbel Charitable Fund
Margaret Munzer Loeb and Daniel Loeb
Merck
Meredith Whitney Advisory Group
Miken Foundation
Catherine and John T. Morse
Park Foundation
Pfizer, Inc.
Julie Turaj and Robert Pohly
Rawley Foundation
Joshua Rosman
Carolyn and Marc Rowan
Rick Rucker — Lawrence County Parkinson’s Association
Elizabeth and Scott Schefrin
Lisa Rotmil and Alex Schmelzer
Hilary Bates and Jerome Simon
The Melvin and Bren Simon Charitable Foundation
Winthrop H. Smith Family Foundation
Anne-Cecilie Engell Speyer and Rob Speyer
Suvyn Family Foundation*
Mildred E. Swanson Foundation
Teva Pharmaceutical Industries Ltd.
Maida and Ralph W. Tyron
Ullmann Family Foundation, Inc.
Viacom International, Inc.
Amy and Fred Weiss
Kimberly Williams-Paisley and Brad Paisley

$10,000 or more
Anonymous
Lisette Ackerberg
Allen & Company
Alpha Search Advisory Partners, LLC
Ammon Foundation
Avenue Capital Group
Barclays Capital
Sylvia M. Becherer
Amanda Peet and David Benioff
Melissa E. Benzuly
Andrea Billhardt
Eric Blecker
Rita and Irwin Blitt
Christina Bloom
Margo and Mitchell Blutt
Donna and Jake Carpenter
Susan and Nicholas Carter
Stephanie and Wayne Caron
Donna and Jake Carpenter
Susan and Nicholas Carter

continued on page 25
MJFF Becomes a Registered Canadian Charity

In 2009, The Michael J. Fox Foundation became a registered, tax-exempt charity in Canada, making all donations to MJFF from Canadian residents tax-deductible to the full extent of the law. Said MJFF founder and Canada native Michael J. Fox, “We have always been fortunate to be on the receiving end of a steady outpouring of Canadian support for our efforts to speed a cure for Parkinson’s. Canadian researchers have also been actively involved in our scientific agenda since our earliest days. It’s tremendously meaningful to me that our Foundation is now an officially registered charity in my home country.” The Foundation is grateful to these Canadian friends for their generosity in 2009.

Doris Adams
Aerial Communications Group, Inc.
Apotex Foundation
James William Ashcroft
Steve Atkinson
Andy C. Barrie
Michele Bebis
The Bitove Foundation
Kathy Blackmore
Francois Bourret
Michael Bregman
Canaccord Capital Corporation
Claire and Jason Capello
Nina Castle
Yves Chabot
James Chmiel
Church Street The Place for Steak
Virginia Cirocco
Catherine E. Clark
Judith L. Cohen
Robert R. Cooper
Sherry S. Cooper
Bruce Cornell
Cossette Communication, Inc.
Creative Colour & Communications, Inc.
Dahlman Rose & Company, LLC
Eleanor and Peter Daniels
Jennifer D’Aoust
Jamin Davies
Lisa de Lusignan
Marc C. Deslongchamps
Distort, Inc.
Heli Donaldson
Karin and Christopher Downie
Downtown Fine Cars, Inc.
Dr. Thomas Morton Medicine Professional Corporation
Rupert J. Duchesne
J. Moffat Dunlap
Emblem
EnerSpectrum Group
Peter Farmer
David Feldman
Frammed Consultants (1993), Inc.
Fraser Milner Casgrain LLP
Paul A. Fredricks
Dr. Bruce V. Freeman
Stanley Fajarzuk
Galin Foundation
Sheldon Garfinkle
GiveMeaning Foundation
Richard Goldberg
Geoffrey Gouinlock
Chris Granman
Griffiths McBurney Canada Corp
Dr. Milan Gupta
Andrew S. Haiberg
Nancy M. Holland
John C. Hamilton
The Paul Hansen Family
Tennys J. Hanson
William H. Hatanaka
Linda Elizabeth Hazen
Endowment Fund
Adam Hegge
Paul Higgins
Jane Hill
Susan E. Hillary
Bethany Hoffman
Beth S. Honowitz
Minnie Horowitz
HSBC Bank Canada
I.P. Rosati Holdings Limited
JTB International (Canada) Ltd.
Justine Blainey Wellness Centre
Jonathan Kaida
Kalex Equipment Services
Dr. Anil Kapoor
Dr. Sunil Kapoor
Mount Allison University
Steve Klassen
KPMG LLP
Krembil Foundation
Roger D. Lace
Esther Lamoureux
Nancy Lang
Christine Leslie
Paul F. Little
Andre Longpre
Matthew MacGregor
Janet Mackinnon
Rosa MacLeod
Malcolm Marcus
Joyce Mason
Sonia and Arun Mathur
Leslie McBeth
Cheryl and Rob McEwen
Mike McPartland
Joseph M. Meaden
Medtronic of Canada Ltd.
Merz Pharma Canada Ltd.
Henry S. Mews
Minuk Construction & Engineering Company
William Moll
Annick Mullen
John Mullen
National Bank Financial Group
Kristy and Eric Nuttall
Thomas J. Obrovic
Osler, Hoskin & Harcourt LLP
Dr. Shekhar Pandey
Parkinson Society Canada
Paul Pathak
Joanna Pedersen
Rebecca Philips
Louise Peloze
Dr. Mani Raman
Mount Allison University
Rivers Reid Ranscombe
RBC Dominion Securities, Inc.
RBC Foundation
Heather M. Regent
Andy Renton
Natalie Rosen
Sage Investments Limited
The Sauder School of Business
Rob Scheiffley
Ianna Selkirk
Hemant Sharma
Erin Sheard
Ferne Sherkin-Langer
Dr. Shaun Singer
Gale Single
Mitra Singh
Dr. Paul Slavchenko
Michael Spanier
Maureen Squibb
St. Joseph Communications
Simon Stanlake
Michael L. Stein
Ronnie Strasser
Carol Grant Sullivan
Charles W. Tellett
Telus Corporation
Levino Tittaferrante
Toronto General & Western Hospital Foundation
Bruce Towler
Caird Urquhart
G. Wesley Voorheis
Deborah Walter
Michael A. Wekerle
Andrea Witzel
Robert D. Wortzman
York University Foundation — Foundation de l’Université York
$10,000 or more (continued from page 23)

The Kay Family Fund
The Keyser Family
Patricia Stonestifer and Michael Kinsley
The George Kress Foundation, Inc.
Jenny Hewlett and Adam J. Kutas
Martha Lam
Amalia and Peter H. Lucas
Tami and Fredric Mack
Janet and Tim Maher
Soania and Arun Mathur
Maverick Capital Foundation
Howard McClure
Trish McEvoy
Debra and Leon Black
Biotechnology industry organization
Charlie and Elaine Gymnich
Bobbi and George Rainwater
Jill and Mark Rachesky
Corky and Stephen Pollan
Estate of Marjorie D. Pippie
the Pioneer Fund
Pergament Education Fund
the geraldine and Eugene PCg Corp.
northern California Parkinson Association of
Jennifer and Sean O'Neal

$5,000 or more
Anonymous (3)
Nina Abrams Fund
Acadia Pharmaceuticals
Sigma Advanced Genetic Engineering (SAGE) Labs
Kenneth Aidekman Family Foundation
AK Steel Foundation
Nonie and Larry Akman Fund of
the Community Foundation for the
National Capital Region
Paul B. Albritton
ALL TRI, Inc.
Jack and Sylvia Altman Foundation
Amicus Therapeutics, Inc.
Marlene and Daniel Arbess
Karen and Gregory Arrese
Babiour Foundation
Lino J. Baiio Trust
Lois Barnard
Mario Batall
Elaine J. Beresh
Robin Berman, MD, and
Ed Berman
Biotechnology Industry Organization
Debra and Leon Black
Dan & Mennie Boone Foundation
The Boston Foundation
Mark J. Boujuukos
Eugenia Brin
Ms. Leila Kamal and Mr. Andrew
Brockway
Brokerage Unlimited Incorporated
Nicole and Brad Brooks
Debi and Jeff Brooks
Brown Charitable Foundation
Bruno-Shayegani Family Foundation
Paul Chan
John Chuck
Bruce Cohen
Gloria Cohen
Stephanie and Chase Coleman
Toby Cooper
Courageous Steps for Parkinson's
CSRA PD Support Group Walkathon
Dawn and Edward D'Alelio
Larry and Anne Davis
Gavin De Becker
Jill and Jeffrey Degen
James G. DelMauro
Mark Dickstein
Ms. Valerie A. DiFebo and Mr. James D. Byrne
The Donegan-Burns Foundation
Mary E. Dooner Foundation, Inc.
Hildeg Drazin
Donald D. Drohny
Catherine Boshaw and Doug Edlund
Drs. Jane and David Eger
Amelia Feinburg
Firman Fund
Bill Fischer
Fowey Light Fund, Inc.
Fox Family Foundation
Pamela and George F. Fox
Lynn and Joel Frank
Joyce A. Friedman
Ron and Linda Galowich
Ellen Gaslow
Kathryn and Oliver Gill
GiveMeaning Foundation
Paige and David Glickman
Deborah and Brian Gottlieb
The Tom and Bonnie Grace Family Foundation
Wally and Charlie Graham
Mr. and Mrs. Alan C. Greenberg
Jeff and Mei Sze Greene Foundation
Laura and William Gruy
Eugene Gurkoff
Jeffrey Hamer
Jonathan M. Harris Family Foundation
Kathy Harris
The Claudia Hearn and Edward Stern Foundation
Wandy and William Hoh
James Holmes
Judith and Michael Hoofstetter
Benjamin and Jessica Hoyt
Jesse Itzler
Lisa and Lamar Johnson
Mr. and Mrs. David O. Jones
Candace Leeds and Ed Katz
Joy and Eric Kaye
Mary and Richard Ketchum
Mary Kilfoy
Kathryn and Richard Kimball
Paul Klinger
Marjorie and Russell Knauer
Mrs. William T. Knight, III
John & Evelyn Kossak Foundation, Inc.
Nyssa and Bill Kourakos
Kramer Levin Naftalis & Frankel LLP
Guymon Casady and Eric Kranzler
Christina and Barry Kringle
Esther Lamoureux
Linda and Alan Landis
Lark Hall Films
Blanche & Irving Laurie Foundation
Dr. and Mrs. Lawrence E. Lee
Lee Family Fund
The Leibowitz & Greenway Family Charitable Foundation
Gloria Levine & Harvey Levine Charitable Foundation
Kathy and Michael J. Lewis
Light Of Day Foundation
Holly and Jonathan Lipton
Deborah and Jim Long
M & T Trust
Robert Macklin
Eilym and Michael Maguire
Roxanne Majka
Make It Possible Foundation, Inc.
Marla Meg Gordon, Konstein Veisz
Wexler & Pollard, LLP
Mary and Robert Mandell
Gary Marks
Kathleen Kennedy and Frank Marshall
John and Maudie Matouk Charitable Foundation
Mayer Family Foundation
Cindy and Mike McConnell
Helen M. McGinn
$5,000 or more (continued from page 25)

Stefanie Meisel and Scott Macklin
Jodi and Kenneth Meister
Merkle Response Management Group
Leo Miller Family Foundation
Estate of May Moore
Carolyn Moran
Elizabeth Moran
Donald Mullen
Beth and James Kevin Murray
George M. Murray, III Revocable Trust
John P. Munnin
Muskim Family Foundation
The Andrew Nagel and
David Brodsky Fund
Tracy and Larry Nagler
Robert D. Nankervis
Jack Nash
Joyce and William Niles
Julie and Scott Ohlman
Marlene Oshoff
Mary Anne and Jim Ostrenga
Leslie B. Otten
Parkinson’s Resources of Oregon
Denise and Donald Paulus
Barbara H. Pekow
Peterson Foundation For Parkinson’s
Justin Pines
James and Virginia Pitts
Lea and Barry Porter Fund
Mrs. Jeanne F. Coleman and Mr.
Lawrence F. Portnoy
Dr. and Mrs. Mukesh Prasad
The William L. Price Charitable
Foundation
Stephen P. Rader and Family
Bradley L. Radoff
Linda and Richard Reiss
Katherine and Michael Renoff
The Rhodes Foundation
Edward Robinson
Sharon and Scott Robinson
William Rosenbaum
Shani and Doug Rothschild
Royal Capital Management
Samaritan Fund
Harriet Saubel
Jennifer M. Schneck
Manuel Schneider Living Trust
Cheryl and David Schreiner
Lynda Breceke and Rick Schwartz
Mark Seliger
The Shack Sackler Family
Frank Selvaggi and William Shea
Jack Shenkman Trust
Lawrence Butler
Patricia and Alfred Byrnes
California Jurisdictional Convention
Linda and Alexander L. Cappello
Jock Casassus
Ruth Jones Casey Foundation
Ceregene, Inc.
Yves Chabot
Linda and Bernard Chalfin
Charina Foundation, Inc.
J. Dawn and Mark Christman
Church Street The Place for Steak
Stacy and Richard Clark
William Connelly
Roger Cooper
Cornt Products International
William Curtis
Kimberly Ann Davis
Mr. and Mrs. Maged Diab
Tim Disney
Silvia and Kevin Dretzka
Sheyel Eberhardt
Linda and Richard Ellis Family
Kathy Emmerson
Neil Everman
Helen Ficalora
Jean and Richard Fiesinger
Michele and Drew Figdor
Toby and Oscar Fitzgerald
Debby and Lou Flancbaum
Rayma and William Flint
Nelle and John Fortenberry
Mark Frey
Sharon N. Freytag
Joan Frost
Lori and Simon Furie
Ronald Garriques
Alan Gates
Beverly and Herb Gelfand
Laurel and George Gerhat
Robert Gersh
The Glen Oaks Philanthropic Fund
Elaine and Brenner Glickman
Mindy and Jeff Glickman
Lisaanne and Howard Godnick
Dawn and Jim Goldfarb
Nancy Jane and Mark Goldston
Estate of Rafael Joseph Gonzalez
Camille E. Granato
Ryan Grant
The George & Reva Graziaiio
Foundation
Vicki and Michael Gross
Adele and Mark Hart, Jr.
Nancy Hausman
June M. Haverly
Sharra L. Haynes
Health Advances, LLC
Sheila and Jonathan Herr
Daniel Herz
Tom Heymann
Craig Hill
Mark Hoffman
Katie and Phil Holthouse
Rusty Holzer
Katie and Aaron Hood
Austin Hope
David Hornkohl
Pat and Shirley Howe Fund
Jill and Stuart Hurwitz
Leslie Weisberg and James Hyman
IBM Corporation
Illinois Shotokan Booster Club
International Precious Metals Institute
Dr. Brenda M. Ivker, PhD
J.C. Kellog Foundation
Deb and Tim Jacobus
Jamakee Foundation
The Joelson Foundation
Harry Johnson
Josfio Corporation
JTB International (Canada) Ltd.
Dora and Neil Kadisha
Tigraw Kastenberg
Seow K. Kek Thay
Eyssa Kellerman
Michael H. Kelson
Harris and Eliza Kempner Fund
Kings Oil Tools Incorporated
Natalie and Brian Kirkdoffer
Bonnie and Bradford Klein
Michael A. Kolodny
David A. Kovner
Joanne and Roger Kozberg
Judy and Joseph Lammastra
Lambert Family Foundation
Jeffrey R. Leake
Phillip E. Ledin
Wallace R. and Bernice E. Leslie
Memorial Fund
David and Julie Levine Family
Philanthropic Fund
Norman H. Levine
The Jack R. Linsky Foundation
Marshall and Carolyn Litchmann
Susan and Preston Lowe
The MJFF Legacy Circle

The Legacy Circle honors friends who support the Foundation’s work through bequests or other planned gifts. While MJFF’s mission has always been to put itself out of business by curing PD, planned gifts provide a major, long-term funding source that we can both plan around, and leverage immediately, to accelerate high-impact research.

<table>
<thead>
<tr>
<th>Donor Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anonymous (8)</td>
</tr>
<tr>
<td>Sylvia Marie Becherer Revocable Living Trust</td>
</tr>
<tr>
<td>Richard Belman</td>
</tr>
<tr>
<td>Lorri Boetto</td>
</tr>
<tr>
<td>Virginia Brooks</td>
</tr>
<tr>
<td>Jock Casasus</td>
</tr>
<tr>
<td>Cal Chadwick</td>
</tr>
<tr>
<td>Frederick C. Colton</td>
</tr>
<tr>
<td>Frances Reser Coody in memory of John Lester Coody</td>
</tr>
<tr>
<td>Anne and Larry Davis</td>
</tr>
<tr>
<td>Rudy and Jane DiNanzio</td>
</tr>
<tr>
<td>Estate of Sam Anderson</td>
</tr>
<tr>
<td>Estate of Lisa Susan Baricelli-Kureen</td>
</tr>
<tr>
<td>Estate of Helen Bennett</td>
</tr>
<tr>
<td>Estate of Ruth Carter</td>
</tr>
<tr>
<td>Estate of Alma Chitwood</td>
</tr>
<tr>
<td>Estate of Catherine Ciocca</td>
</tr>
<tr>
<td>Estate of Diane Mae Clark</td>
</tr>
<tr>
<td>Estate of Josephine M. Cretnik</td>
</tr>
<tr>
<td>Estate of Henry Czerwic</td>
</tr>
<tr>
<td>Estate of Beryl Deming</td>
</tr>
<tr>
<td>Estate of Marjory S. Fellman</td>
</tr>
<tr>
<td>Estate of Rafael J. Gonzalez</td>
</tr>
<tr>
<td>Estate of Richard Gorman</td>
</tr>
<tr>
<td>Estate of Iva Pauline Hancock</td>
</tr>
<tr>
<td>Estate of Pollyanna Herrell</td>
</tr>
<tr>
<td>Estate of Helen Hoskin</td>
</tr>
<tr>
<td>Estate of Jack Kellogg</td>
</tr>
<tr>
<td>Estate of John Christopher Kimmey</td>
</tr>
<tr>
<td>Estate of Dolores E. Kossak</td>
</tr>
<tr>
<td>Estate of Louis Krieger</td>
</tr>
<tr>
<td>Estate of Raymond H. Lake</td>
</tr>
<tr>
<td>Estate of Dorothy Lesher</td>
</tr>
<tr>
<td>Estate of Deb Lipton</td>
</tr>
<tr>
<td>Estate of Byron Mavrakis</td>
</tr>
<tr>
<td>Estate of Geraldine McMillan</td>
</tr>
<tr>
<td>Estate of Edna May Minnick</td>
</tr>
<tr>
<td>Estate of May Moore</td>
</tr>
<tr>
<td>Estate of Sidney Kanz Morgan</td>
</tr>
<tr>
<td>Estate of Martin Nash</td>
</tr>
<tr>
<td>Estate of Don and Ruth Palmer</td>
</tr>
<tr>
<td>Estate of Jean Patton</td>
</tr>
<tr>
<td>Estate of Marjorie Pippie</td>
</tr>
<tr>
<td>Estate of Melvin Rauch</td>
</tr>
<tr>
<td>Estate of Marjorie Richards</td>
</tr>
<tr>
<td>Estate of Eileen R. Salter</td>
</tr>
<tr>
<td>Estate of Lucile Traeger</td>
</tr>
<tr>
<td>Estate of Melvin S. Zuckerman</td>
</tr>
<tr>
<td>Janet and Robert B. Ettleman</td>
</tr>
<tr>
<td>Jeff Evans</td>
</tr>
<tr>
<td>Barbara Folender</td>
</tr>
<tr>
<td>The Donald and Martha B. Geibel Trust</td>
</tr>
<tr>
<td>Margaret C. Glasser Trust</td>
</tr>
<tr>
<td>Peter Gonsalves</td>
</tr>
<tr>
<td>Juan Griego</td>
</tr>
<tr>
<td>The Frederick W., Norma G., and Janet L. Grill Family Endowment Fund</td>
</tr>
<tr>
<td>Andrew S. Grove</td>
</tr>
<tr>
<td>Thomas K. &amp; Yvonne G. Hanes Charitable Remainder Trust</td>
</tr>
<tr>
<td>Richard Henriksen</td>
</tr>
<tr>
<td>Lee Herman</td>
</tr>
<tr>
<td>Mary Hopkins</td>
</tr>
<tr>
<td>The Hoover Family Charitable Remainder Trust</td>
</tr>
<tr>
<td>Judy and Charles A. Huss</td>
</tr>
<tr>
<td>The Grace Richardson Jones Trust</td>
</tr>
<tr>
<td>Eleanor Frances Nelson Jordan</td>
</tr>
<tr>
<td>The Jerry Katz Trust</td>
</tr>
<tr>
<td>Rev. Dolores K. Kimsey</td>
</tr>
<tr>
<td>Rose Krieger</td>
</tr>
<tr>
<td>Jim and Deborah Long</td>
</tr>
<tr>
<td>Sally and Andrew Lorenz</td>
</tr>
<tr>
<td>Robert G. Lusk</td>
</tr>
<tr>
<td>The Edmund Ernst McClure Trust</td>
</tr>
<tr>
<td>Elizabeth Murphy</td>
</tr>
<tr>
<td>Karen Oliver</td>
</tr>
<tr>
<td>The Margaret Paul Trust</td>
</tr>
<tr>
<td>John Richard Randall</td>
</tr>
<tr>
<td>Larry Randall</td>
</tr>
<tr>
<td>Estelle Randolph</td>
</tr>
<tr>
<td>Gail Reeves</td>
</tr>
<tr>
<td>Judith Snow Reidel</td>
</tr>
<tr>
<td>The Efthelia Remlinger Revocable Living Trust</td>
</tr>
<tr>
<td>Thomas Sabourin</td>
</tr>
<tr>
<td>Karen Schneider</td>
</tr>
<tr>
<td>Manuel Schneider Living Trust</td>
</tr>
<tr>
<td>Sean Sidway</td>
</tr>
<tr>
<td>Henry F. Spector</td>
</tr>
<tr>
<td>Dorothy Straus</td>
</tr>
<tr>
<td>The Gilbert Strong Trust</td>
</tr>
<tr>
<td>The Sutherland Family</td>
</tr>
<tr>
<td>The Teitelbaum Family Trust</td>
</tr>
<tr>
<td>The Sophia Tomich Trust</td>
</tr>
<tr>
<td>The John D. Turkel Revocable Trust</td>
</tr>
<tr>
<td>Alessio and Flora Ventura</td>
</tr>
<tr>
<td>Margareth M. Wall</td>
</tr>
<tr>
<td>Dr. Brent and Terry Weinberger</td>
</tr>
<tr>
<td>Elizabeth H. Weinraub</td>
</tr>
<tr>
<td>The Dotha S. Welbourn Charities Trust</td>
</tr>
<tr>
<td>The Charles C. White Revocable Trust</td>
</tr>
<tr>
<td>Kathryn P. Wright</td>
</tr>
<tr>
<td>Yacuone Living Trust</td>
</tr>
</tbody>
</table>

If you have made estate plans that include MJFF and would like to be listed as a member of The Legacy Circle, please call Karen Leies at (212) 509-0995, ext. 269.
$2,500 or more (continued from page 27)

Charles Scott
Jeff Seabold
Michele and Kenneth Seim
Kevin Sheehan
Robert Sholtz
Glen and Amy Siegel
Silks Foundation, Inc.
Linda and J.R. Sims
Rita Sklar
Jude and Joseph Smith
Maureen and Glen Smith
Delores and Isaac Soffer
Solomon Family Foundation
Sound Sight Technologies, Inc.
South Valley Civic Theatre
Margaret P. Stevenson Foundation
Stolper Family Trust
Rose and Richard Straeter
Lisa and Scott Stuart
Summit County Parkinson’s Support Group
Sundance Running Club
Ram Sudaram
Dr. S. Jerome and Judith D.Tamkin
Lisa and Steven Tananbaum Family Foundation
Tarshis Family Foundation
The Adam USDAF 2006 C.L.A.T
The Kallis Family Charitable Foundation
Elizabeth and Dennis Tito
Gail and Richard Ullman
Meredith and Bryan Verona
Judy Wada
Sally Washburn
Anne and William Washychyn
Bradley J. Wechsler
Norma and Ed Weinman
Linda and Patrick Welch
Diane Wilsey
Jan and Eddie Woods
Billy Wooters
Ken Wormser
Mr. and Mrs. Wayne R. Zdenek
Jeannie and Terrence Zehrer

$1,000 or more
Anonymous (18)
Nancy and Colman Abbe
Denise and Herb Abrash
Jorge Acquaviva
Aeroquip Credit Union
Aggressive Heating, Inc.
Agron, Inc.
Brenda and Robert Aiken
Roger E. Ailes
Alaska AFL-CIO
Andrew Albert
Eduardo Alcocer
Michelle B. Alfanz
Robert Allard
Andrew Allen
Julie and David Allen
Jean and Harold Allen
Jodie and George Allen
Donald Allman
William E. Alt Charitable Fund
George Amandola
Amedisys Incorporated
American Endowment Foundation
Noni and Charlton Ames
Nora Ammar
Noah J. Anderson
Annette Andrade
Anne and Joseph Andrew
Penny and Marion Antonini
Nino Antuzzi
Sheldon & Carol Appel
Family Foundation
Dane Arden
Jody and John Arnhold
Courtney Cox-Arquette and David Arquette
Sharon Asher
Audio Command Systems, Inc.
Austin Community Foundation
Auto Club Speedway/ Ms. Gillian Zucker
Avad, LLC
The Bacas Family Foundation
Shae Baddour
The Arnold F. Baggins Foundation, Inc.
Lori Pollan and Allan Bahn
Anne B. Baker
Anne Elizabeth Baker
Pamela and Jesse Baker
Leslie and Buck Balkind
Paul C. Baria
John J. Barry
Linda and Douglas Bartlett
Steve Barton
Michael Bartsch
Lee Bass
Mickey Bass
Kathleen C. Bassi
Jerome Simon and Hilary Bates
Beach Equities
Lisa and David Beall
Don C. Bedell
Nancy and Michael Beebe
Dr. Holley A. Belch
Gerry B. Belling Philanthropic Fund
Peter Benedek
Michael J. Bensing
Alfred K. Berg
Susan and Adam Berger
Michael Bernstein
Nancy and John Bertino
Jo Anne and David Bescherer
Jo-Anne and Richard Biolitti
Harvey Bird
Joann M. Bisto
Kathy Blackmore
Clarence and Sheila Blair
Brad Blanchard
Barbara Blanchfield
Carol and Jim Blann
Betty and Ray Blansett
Keith Block
Kristie and Steven Block
Christopher Bloise
Sandi and Jerry Bloomberg
Blue Bell Foundation
John and Myrna Blume
Dr. Maxwell L. & Florence C. Blumenreich Foundation
Boar’s Head Brand Cassametta Provisions, Inc.
Bobo Jetmundsen Foundation
Bock & Associates, LLC
David Bohmert
Robin Bond
Joseph F. Boulos
Francois Bourret
Scott Boxer
Tom and Leann Boyan
Mark Boyd
Norm and Linda Boyer
Marcia and Dennis Brager
David S. Brammer
Shirley and John Bandy
Dwight Brannon
Brenda and Robert Brantley
Braude Foundation
David B. Breed
Janet M. Breedlove
Daniel Brewer
Bricker & Eckler, LLP
Bridgewater Associates, Inc.
Nicolas Brien
Devon and Peter Briger
Jared Brimfield
The Judy & Bernard Briskin Fund
Lynn A. Brody
Ellen and Peter Brody
John F. Brown
Lisa and Steve Brown
Diana Browner
Keith N. Browning Family Foundation
Beatrice Bruce
Christian Buckner
Sandra and Peter Bruhn
Horst Brunner
Mr. and Mrs. Steven C. Bryant
Janis and Wiley Buchanan
Dana Buchman
Beverly and James Buckley
Kay and Matthew Bucksbaum
Christine Bulawa
Otis Burdine
Laura Kang and Paul Burkhead
Emily W. Burns
Burr and Forman, LLP
Eugenia and George Burylo
Lloyd Byars
Celia M. Byrne
The Harman Cain Family Foundation
Brendan Callahan
Carol S. Callahan
Barbara and Roger Calvert
Donald Cantway
Elaine and Elliott Caplow
The Caravan Trust
Sandy Carey
Ian T. Carnathan
Donna Carpenter
Cheryl and Steven Carver
Casey Family Advised Fund
Peter Catalano
Dawn and Rocky Caullwine
Barbara and Anthony Celeste
Centre Reinsurance
Sara and Joe Cerrell
Jacquelyn Chandler
Robert T. Chang
Charitable Foundation Trust
Charitybuzz
Carol Chase
Lance H. Chau
Alfred Checchi
Marissa and Saj Cherian
Harry Chemin Foundation
Helena Christensen
William Christie
Steven Chrzanowski
Chubb Corporation
The Chutorian-Semer Family Foundation
Pamela Cincotta
Circle of Service Foundation
Gary Cirilli
Ciuni & Panichi Advisors
Robert C. Clare
Claremore Club, Inc.
Erin E. Clark
Sacha Clark
Clayman Family Foundation
Marylnn K. Clayton
Judi and George Clute
The Coffee Bean & Tea Leaf
Louise and Thomas Coffey
Abe M. Cohen Family Foundation
Jeff Cohen
Dena and Steven Cohen
Mr. and Mrs. S. Michael Cohen
George F. Cole
Tracey and Adam Collins
CommerceNet
Competition Corvette Association Incorporated
Compulink Business Systems
Susie and Butch Conen
John C. Conwell
Cooper Sheet Metal
Debi Corbin
Anita Cosgrove
Laurel and John Cravens
Mrs. Joan Creedon
Jeanne and Peter Crisci
Jeremy R. Crisup
Compaq Apartment Homes, LLC
Louis Dahan
Dalio Family Foundation, Inc.
Jan Dallam
Kumaran Damodaran
Diane Danakas-Discoe
Katherine and Costa Darras
The David Family Foundation
Nancy and Russell Davidson
Ellen and Gary Davis
Joey Davis
Scott Davis
Kathryn and Stuart De Haaff
Elizabeth de Ramel
Dick Deery
Karen and Carl deGraaf
David Deibel
Michael De Jong
Susan M. Delago
Gilles and Inge Dellalret
Maureen and Robert Deloury
Paul D. Delva
Robert Denlow
Sarah and Paul Densen
Charitable Foundation
Ginny DePasqua
Robert D’Eustachio
Kimberly Dewalt
Charles Diamond
Jerry Diamondstein
Richard Dickstein
Linda K. Dieken
Jennifer and Joyce Diener
Steve DiFilippio
Distort, Inc.
Don P. Dizen
Judy Dobrowski
Joseph Dorsey
Karen and Christopher Downie
Cicrinda R. Driscoll
Jesse De Bu
Patty and Howard Dubin
Michael Dubin
Stephanie and Brian Dubinsky
James M. DuBois
Patrick and Mary Dunleavy
Dr. and Mrs. Paul P. Dunn
Marsha and Anthony Durniak
Marvin and Jean Durning
Kris Dworoksi
Robert Dworoksi
The Dyer Family
Carole and David Ebner
Stanley Ebner
The Economist Newspaper
The Edgecomb Foundation
Adele Eger
Ronald Eger
Marty and Dale Ehrenreich
Mitzi & Warren Eisenberg
Family Foundation
Mrs. Ethel Eisenberg
Bruce W. Elder
Gail and Jim Ellis
Lisa and Christopher Engel
Charlie Engelke and
Laurie White Fund
Richard England
Joann and Wayne English
Rodney English
Ross Epstein
Elizabeth Ernst
Atilla Ertan
Drew Erftman
Judith and Irving Evall
The Eveslin Family Foundation
Tom Ezaki
Ramsey Fadman
Scott Fahey
Fairwood Financial Services, LLC
Darby and Jason Farmer
Peter Farmer
Stephen E. Farris
Fasnacht Family Foundation
Dennis R. Fay
Bunny and Sy Feigenbaum
Joan and William Feldman
William Fellows
Fidelity Charitable Gift Fund
Albert L. Fierro Sr. Charitable
Foundation
Esther Baird and Stanley Fimberg
Magdalen Fisher
Peggy and Dick Fitzgerald
Andrew Fitzgerald and Richard
Fitzgerald
Timothy Fitzgibbons
Irene and David Flaum
Maria and Raymond Floyd
The Ellen M. and Lawrence B.
Floyd Family Foundation
Deirdre Flynn
Kenny Foo
The Ford Family Foundation
Mary Ann Forman
Amy Foster
The Connie Frank Foundation
Bruce and Kipp Freeman
Katherine Fresko
Andrew and Brooke Friedman
Edna Frigo
Judge Hilda R. Gage
Roy Gagnon
William Gaine
Jane and Robert Gallagher
Patricia and Lawrence Galloway
Gans-Mex, LLC
Richard Garber
Ken Garschina
Jerry Geldernick
Mary and Peter Gens
Pat and Charles Genuardi
George Weintraub & Sons, Inc.
Marilyn Gerber
Joan L. Germany
Leslie and Morton Gerson
Steven Gerstung
Lisa and Rick Giacco
Suzi and Steve Gilbert
Deborah and Donald Gill
Michael Gillen
Mike Ginsberg
GlaxoSmithKline
Shirley Gleich
Kathy and Robert Glickman
Justin Gmelich
Stuart Goldblatt
Mitchell and Lenore Goldstein
Barbara M. Goodbody
Sandra and Allen Gookin
Mark Gordon
James and Meg Gordon
Judith and Sheldon Gordon
James and Penny Gorman
Irwin Gottlieb
Thomas Gottlieb & Carol Kirsh
Family Fund
The Gould-Shenfeld Family Foundation
The Grace Jones Richardson Trust
Grand Temple #15 Pythian Sisters NYC
Grange Kitchen and Bar
Alison and Andrew Gratz
Mr. and Mrs. Bennett Grau
Erica and Kenneth Grau
Marisa and Edward O. Green
Zoe and Steve Green
Theodora and Robert Greenbaum
Sandy and Irwin Greenberg
The Martin B. Greenberg Foundation
Sheila Greenberg
Nancy S. Greene
Greenlight Foundation
Sherwin Greenwald
Donald E. Greenway
Sharon Gregorczyk
Edward W. Griffin Memorial Fund
Clark Grimm
Glenn Grossman
Deborah and Allen Grubman
Kevin Gruber
Charlotte and Larry Gustavson
Robert Haber
Cindy and James Hadaway
Barbara and Ed Haddad
Mallory and Peter Haffnerfeller
Lia and Bruce Hager
Ginger and Larry Hahn
Amy and David Halliburton
continued on page 30
<table>
<thead>
<tr>
<th>$1,000 or more (continued from page 29)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Halperin Foundation</td>
</tr>
<tr>
<td>Jeremy Halpern</td>
</tr>
<tr>
<td>Don and Mary Jane Hamaker</td>
</tr>
<tr>
<td>Rodney N. Hamilton</td>
</tr>
<tr>
<td>The Hamilton Foundation, Inc.</td>
</tr>
<tr>
<td>William Hamm</td>
</tr>
<tr>
<td>Andrea and John Hampshire</td>
</tr>
<tr>
<td>Rita Wilson and Tom Hanks</td>
</tr>
<tr>
<td>Rochelle Hanna</td>
</tr>
<tr>
<td>Stan Hannah</td>
</tr>
<tr>
<td>Trish Hanson</td>
</tr>
<tr>
<td>Harbor Casino Bar Restaurant, LLC</td>
</tr>
<tr>
<td>Eric Hardey</td>
</tr>
<tr>
<td>Judy and Joseph Harding</td>
</tr>
<tr>
<td>Susan and Richard Hare Family Foundation</td>
</tr>
<tr>
<td>Ethel and Samuel Hartman</td>
</tr>
<tr>
<td>Harmon Family Trust</td>
</tr>
<tr>
<td>Ron Harner</td>
</tr>
<tr>
<td>The Hamisch Foundation</td>
</tr>
<tr>
<td>Harper Collins Publishers</td>
</tr>
<tr>
<td>Jeremiah T. Hart</td>
</tr>
<tr>
<td>Brenda Harter</td>
</tr>
<tr>
<td>Kristy and Rob Hartoveldt</td>
</tr>
<tr>
<td>Harvard University</td>
</tr>
<tr>
<td>Michelle and Hugh Harvey</td>
</tr>
<tr>
<td>Peter and Tina Hayward</td>
</tr>
<tr>
<td>Linda Elizabeth Hazen Endowment Fund</td>
</tr>
<tr>
<td>Robin and Daniel Hedlund</td>
</tr>
<tr>
<td>Andrea and Ron Hein Charitable Fund</td>
</tr>
<tr>
<td>Jeff Hitzner</td>
</tr>
<tr>
<td>Betty and Irwin Helford</td>
</tr>
<tr>
<td>Cathy Duffy and Frank Heller</td>
</tr>
<tr>
<td>Robert Helsgott</td>
</tr>
<tr>
<td>Andrej-Nicolai Henkler</td>
</tr>
<tr>
<td>Lee Henson</td>
</tr>
<tr>
<td>James and Marjorie Herald</td>
</tr>
<tr>
<td>Debra Hernberg</td>
</tr>
<tr>
<td>Jim D. Herrgesell</td>
</tr>
<tr>
<td>Maureen and Michael Hess</td>
</tr>
<tr>
<td>David Hidalgo, M.D.</td>
</tr>
<tr>
<td>Peggy and Richard Hieter</td>
</tr>
<tr>
<td>High Five Foundation</td>
</tr>
<tr>
<td>The Hill Family Charitable Foundation</td>
</tr>
<tr>
<td>Hillard Farber &amp; Co., Inc.</td>
</tr>
<tr>
<td>Susan E. Hillery</td>
</tr>
<tr>
<td>Linda and Mike Hinkle</td>
</tr>
<tr>
<td>Judith E. Tschirgi and Steven J. Hoch</td>
</tr>
<tr>
<td>Kay and Grey Hodnett</td>
</tr>
<tr>
<td>David L. Hoffman</td>
</tr>
<tr>
<td>Laurie and Matthew Hogan</td>
</tr>
<tr>
<td>Greg Holden</td>
</tr>
<tr>
<td>Robert Holo</td>
</tr>
<tr>
<td>Samuel and Hannah Holzman Trust</td>
</tr>
<tr>
<td>Honey Farms, Inc.</td>
</tr>
<tr>
<td>Keith A. Hoover</td>
</tr>
<tr>
<td>Mary Hopkins</td>
</tr>
<tr>
<td>Joan Hotchkiss</td>
</tr>
<tr>
<td>The Mary L. House Charitable Gifts</td>
</tr>
<tr>
<td>Lina Hu</td>
</tr>
<tr>
<td>Hub International Northeast Limited</td>
</tr>
<tr>
<td>Carol and Frank Huber</td>
</tr>
<tr>
<td>Leane and Gerald Huichital</td>
</tr>
<tr>
<td>Paul Huchno</td>
</tr>
<tr>
<td>Hudson Housing Capital, LLC</td>
</tr>
<tr>
<td>The Huisking Foundation, Inc.</td>
</tr>
<tr>
<td>Dennis and John Humphrey</td>
</tr>
<tr>
<td>Juanita C. Humphrey</td>
</tr>
<tr>
<td>Elizabeth Hunter</td>
</tr>
<tr>
<td>Ryan Huskey</td>
</tr>
<tr>
<td>Judith and Charles Huss</td>
</tr>
<tr>
<td>Holly and Thomas Huth</td>
</tr>
<tr>
<td>I Do Foundation</td>
</tr>
<tr>
<td>Leonard Iacono</td>
</tr>
<tr>
<td>ICAP Services North America, LLC</td>
</tr>
<tr>
<td>Independent Bank</td>
</tr>
<tr>
<td>David B. Ingrey</td>
</tr>
<tr>
<td>Sharyl and Roy Inlow</td>
</tr>
<tr>
<td>Lesley Innes</td>
</tr>
<tr>
<td>International Precious Metal Institute</td>
</tr>
<tr>
<td>New York</td>
</tr>
<tr>
<td>Clifford W. Ishmael</td>
</tr>
<tr>
<td>ITG, Inc.</td>
</tr>
<tr>
<td>Valerie Frost-Atkins and Robert Iverson</td>
</tr>
<tr>
<td>Larry Jacobson</td>
</tr>
<tr>
<td>Linda and Denny Jacobus Family</td>
</tr>
<tr>
<td>Marc and Karen Jaffe</td>
</tr>
<tr>
<td>Sheryl L. Jedlinski</td>
</tr>
<tr>
<td>The Sidney D. Jeffe Trust</td>
</tr>
<tr>
<td>Sheila Jefferson</td>
</tr>
<tr>
<td>Suzie and Max Jellinek</td>
</tr>
<tr>
<td>Michael A. Jessew</td>
</tr>
<tr>
<td>Jewish Community Fund</td>
</tr>
<tr>
<td>Jewish Community Foundation</td>
</tr>
<tr>
<td>Barbara and Mike Johnson</td>
</tr>
<tr>
<td>Carol Johnson</td>
</tr>
<tr>
<td>Elaine Joost</td>
</tr>
<tr>
<td>The Jordan Company, L.P.</td>
</tr>
<tr>
<td>DeNine and Robert Jordan</td>
</tr>
<tr>
<td>Steven R. Jordan</td>
</tr>
<tr>
<td>William H. Josephs</td>
</tr>
<tr>
<td>Sheryl Josephson</td>
</tr>
<tr>
<td>Matthew Joy</td>
</tr>
<tr>
<td>Dr. Scott Kadlec</td>
</tr>
<tr>
<td>Sharon Kaelin</td>
</tr>
<tr>
<td>Stephen and Laurie Kafka</td>
</tr>
<tr>
<td>Kahn Foundation</td>
</tr>
<tr>
<td>Robert J. Kahn Foundation</td>
</tr>
<tr>
<td>Richard Kaminsky</td>
</tr>
<tr>
<td>G. Kanda</td>
</tr>
<tr>
<td>Thomas Kandel</td>
</tr>
<tr>
<td>Stephen F. Kaney</td>
</tr>
<tr>
<td>Sally and Paul R. Kanin</td>
</tr>
<tr>
<td>Carol G. Kaplan</td>
</tr>
<tr>
<td>Ruth and Jess Karter</td>
</tr>
<tr>
<td>Karen Katen Foundation</td>
</tr>
<tr>
<td>The Jerry Katz Trust</td>
</tr>
<tr>
<td>Beth and Brett Kaufman</td>
</tr>
<tr>
<td>Andrea Kay</td>
</tr>
<tr>
<td>Lauren, Dave, Brady and Reagan Kay</td>
</tr>
<tr>
<td>Bryan and Meg Keen</td>
</tr>
<tr>
<td>Gina Keenan-Hepke</td>
</tr>
<tr>
<td>Douglas Kegler</td>
</tr>
<tr>
<td>Joel and George Keim</td>
</tr>
<tr>
<td>Yvonne Kellar-Guenther</td>
</tr>
<tr>
<td>Katrina and Pat Kelley</td>
</tr>
<tr>
<td>Jed Kelly</td>
</tr>
<tr>
<td>Mary Kelly</td>
</tr>
<tr>
<td>Arline and Robert Kennedy</td>
</tr>
<tr>
<td>Sara Kenny</td>
</tr>
<tr>
<td>James M. Kerr</td>
</tr>
<tr>
<td>Dana and Richard Kind</td>
</tr>
<tr>
<td>Dr. Betty R. King</td>
</tr>
<tr>
<td>Kings Drug and Surgical</td>
</tr>
<tr>
<td>Kings Park Slope, Inc.</td>
</tr>
<tr>
<td>Scott Kingsley</td>
</tr>
<tr>
<td>Shawn Kingsley</td>
</tr>
<tr>
<td>Michael Kinney</td>
</tr>
<tr>
<td>Margie and Weldon Kirby</td>
</tr>
<tr>
<td>Rebecca A. Kirk</td>
</tr>
<tr>
<td>Laurie C. Kissell</td>
</tr>
<tr>
<td>The Kenneth And Laurie Kissel Charitable</td>
</tr>
<tr>
<td>Foundation</td>
</tr>
<tr>
<td>Leonard Kleiman</td>
</tr>
<tr>
<td>Matt and Susan Klein</td>
</tr>
<tr>
<td>Valerie Klein</td>
</tr>
<tr>
<td>Barbara and Leonard Kodol</td>
</tr>
<tr>
<td>The Donald C. and Norma</td>
</tr>
<tr>
<td>(Klug-French) Allyn Fund of the Lutheran</td>
</tr>
<tr>
<td>Community Foundation</td>
</tr>
<tr>
<td>Gisela Knijnenburg</td>
</tr>
<tr>
<td>Kevin Koch</td>
</tr>
<tr>
<td>John N. Kogan</td>
</tr>
<tr>
<td>Marguerite and Morton M. Kondracke</td>
</tr>
<tr>
<td>Norman Konner</td>
</tr>
<tr>
<td>Elizabeth and Ken Kopelman</td>
</tr>
<tr>
<td>Paul Korman</td>
</tr>
<tr>
<td>Mary Beth and Robert Kors</td>
</tr>
<tr>
<td>Scott Koster</td>
</tr>
<tr>
<td>Yvette and Roger Kotch</td>
</tr>
<tr>
<td>Selma and Eldon Koznek</td>
</tr>
<tr>
<td>Mitchell Kramer</td>
</tr>
<tr>
<td>Elaine Kranich</td>
</tr>
<tr>
<td>Seth Krauss</td>
</tr>
<tr>
<td>James Kress</td>
</tr>
<tr>
<td>Carole and Hal Kroeger</td>
</tr>
<tr>
<td>Lisa and Clyde Krogh</td>
</tr>
<tr>
<td>Beth and Williams Krumbine</td>
</tr>
<tr>
<td>Kevin M. Kruzenski</td>
</tr>
<tr>
<td>Kucera Family Foundation</td>
</tr>
<tr>
<td>Jon Kuly</td>
</tr>
<tr>
<td>David Kurti</td>
</tr>
<tr>
<td>Randye and Brian Kwait</td>
</tr>
<tr>
<td>Lake Forest/Lake Bluff Junior Women's Club</td>
</tr>
<tr>
<td>Mary Lou and Bill Lange</td>
</tr>
<tr>
<td>Chriscinda and Fabian Lange</td>
</tr>
<tr>
<td>Guy Langevin</td>
</tr>
<tr>
<td>Diane and Jerome Lapham</td>
</tr>
<tr>
<td>Pati and Thomas Larkins</td>
</tr>
<tr>
<td>Pamela and Eric Larson</td>
</tr>
<tr>
<td>Jan and Fred Laughlin</td>
</tr>
<tr>
<td>Laurel Conqueror 451</td>
</tr>
<tr>
<td>Laurel Conqueror Association, Inc.</td>
</tr>
<tr>
<td>Smeller Scholarship Fund</td>
</tr>
<tr>
<td>Verna and Neil Laurin</td>
</tr>
<tr>
<td>Bonnie Englebardt Lautenberg</td>
</tr>
<tr>
<td>Joe Lavi</td>
</tr>
<tr>
<td>James E. Lee</td>
</tr>
<tr>
<td>Debra Peralda and Robert Lemon</td>
</tr>
<tr>
<td>Len Camber Grantor Trust</td>
</tr>
<tr>
<td>Charles and Margaret Levin Family Foundation, Inc.</td>
</tr>
<tr>
<td>Wendy and Barry Levin</td>
</tr>
<tr>
<td>Becky and Mark Levin</td>
</tr>
<tr>
<td>The Richard L. Levin Family Foundation</td>
</tr>
<tr>
<td>Lola J. Perniceiaro and Mark A. Levine</td>
</tr>
<tr>
<td>Elayne and Howard Levkowski</td>
</tr>
<tr>
<td>Edward and Jami Levy Foundation</td>
</tr>
<tr>
<td>Peter Li</td>
</tr>
<tr>
<td>Jillian Libenson</td>
</tr>
<tr>
<td>Seth Lieberman</td>
</tr>
<tr>
<td>Anita and Stanley Liebowitz</td>
</tr>
<tr>
<td>Fred W. Limbach</td>
</tr>
<tr>
<td>Karen and Mark Limbird</td>
</tr>
<tr>
<td>Pam Lindroos</td>
</tr>
<tr>
<td>Stuart Liner</td>
</tr>
<tr>
<td>Annette P. Lintz</td>
</tr>
<tr>
<td>Paul F. Little</td>
</tr>
<tr>
<td>The Litwin Foundation</td>
</tr>
<tr>
<td>Linda and Robert Livingston</td>
</tr>
<tr>
<td>Local 147 Tunnel Workers</td>
</tr>
</tbody>
</table>
2009 Matching Gift Companies

Abbott Laboratories, Employee Giving Campaign
Aetna Foundation, Inc., Partners in Community Giving
Allstate Giving Campaign
American Express Foundation Company Employee Giving Campaign
America’s Charities, Inc.
Ameriprise Financial Employee Giving Campaign
Ameriprise Financial Matching Gift Program
The Amgen Foundation
Anheuser Busch, Inc.
Bank of America Charitable Foundation
Bank of America United Way Campaign
The Bank of New York Mellon Community Partnership
Bank of the West
Bill & Melinda Gates Foundation
The Black & Decker Corporation
Boeing Company Employee’s Community Fund
Bristol-Myers Squibb Company Employee Giving Program
The Capital Group Companies Charitable Foundation
Cardinal Health Foundation, Inc.
Chubb & Son
Coastal Georgia Combined Federal Campaign
Davis Selected Advisers, L.P.
Dell Direct Giving Campaign
Employees Charity Organization
Employees Community Fund of the Boeing Company
Evanston Capital Management, LLC
The Ford Foundation Matching Gift Program
GE Foundation
Give With Liberty
GlaxoSmithKline
Global Impact
Goldman, Sachs & Co. Matching Gift Program
Google
Greenlight Capital, Inc.
Harvard University
Hewlett-Packard
Honeywell Hometown Solutions
IBM Employee Services Center
Independent Charities Of America
ITF Foundation
John Hancock Financial Services, Inc.
Johnson & Johnson Family of Companies Matching Gifts Program
JPMorgan Chase
Keefe, Bruyette & Woods, Inc.
Kraft Foods Foundation Matching Gifts Program
KTVA-TV
Lone Pine Capital, LLC
Lumina Foundation for Education
The McGraw-Hill Companies Employee Giving Campaign
Merk Partnership for Giving
Merrill Lynch & Co. Foundation, Inc.
Matching Gift Program
Microsoft Corporation Matching Gift Program
Morgan Stanley
Mutual of America
National CineMedia, LLC
Nestle Foundation
Pepsi-Cola Company
Pfizer United Way Campaign
Portland General Electric Company
The Prudential Foundation Matching Gift Program
The Robert Wood Johnson Foundation
Sabre Holdings United Way Campaign
Sanofi Aventis Matching Gifts Program
Takeda Pharmaceuticals Employee Giving Campaign
Tri-State Health Association
United Way of Allegheny County
United Way of Delaware
United Way of Greater Twin Cities
United Way of New York City
United Way of Somerset County
United Way of Southeastern Pennsylvania
United Way of the Bay Area
United Way of the Columbia-Willamette
United Way of Tri-State
Valley of the Sun United Way
Verizon Foundation
Washington Mutual Employee Giving Program
Wellpoint/Unicare Associate Giving Campaign
Wells Fargo Community Support Campaign
XL Reinsurance America, Inc.

We are grateful to these companies for their generosity in matching employee gifts to MJFF, resulting in a total match of about $200,000 in 2009.
$1,000 or more (continued from page 31)

Chris and Linda McKenney
The McKinney Charitable Trust
Peter McKown
Michael B. McMahen
James J. McNasby
Mary McNaught
Joseph M. Meaden
Medicus Foundation
Mary Meeker
Christopher Mellon Family Fund
John C. Mendillo Family Foundation, Inc.
Sue and Fred Menowitz
Rosellen and Barry Mensch
Charles E. Mensing
Mary Meola
Annette Merle-Smith
Betty and Robert Mero
Patricia A. Merrill
Bruce Meyer
The Meyer Family Fund
Micanopy Area Chamber of Commerce
Fran Middlemian
Susan Bartsch and Robert Mileti
Brian Miller
Janice Miller
Steve Miller
The Miller Family Fund
Joanne McElligott and Douglas Millett
Missionfish-Polf
Phillip Mitteldorf
Andrea and Michael Mohr
Shelly and Frederick Molineux
Phyllis Molyneux
Sarah Orsay and Russell Montalbano
Ann B. Moore
Olga and Thomas Moreland
David E. Morey
The Moroze Family Fund
Dwight and Susan Morrow
Lou Moskowitz
Tim and Emily Moutlon
MSR Advisers, Inc.
John Mullen
William A. Mundell
Wendy Munger
Maureen O'Callaghan-Murphy and John Murphy
John D. Murphy
Mark Murphy
Mary Murphy
Marlene H. Murtonen
Richard Muscio
Thomas C. Muse
Kary and Gary Myers
NAMSB Foundation, Inc.
National CineMedia, LLC
National Madison Group, Inc.
Michael Naumann
Hedy and Benjamin Nazarian
Margaret and LeRoy Negus
Merle and Leonard Nelson
Richard P. and Faye Nespola Charitable Foundation
Mary and Alexander Navab
New England Research and Management, Inc.
Newark Asphalt Corporation
Sally Nichols
Joan C. Niedfeldt
Anne and Thomas Niesen
Jeffrey M. Nobel
Ann and George Norris
Virginia W. Norris
Richard Nunnelly
Kristy and Eric Nuttall
Ruby and Jack Obenauer
Edward O'Connell
Brenda and Budge Offer
Kit and Roger Olen
Stephen Olentine
Madeleine D. O'Mara
Toni Oesting
Minna and Duncan Orrell-Jones
Gerald Ouderkerk
Robert Ousterhout
Oxford Industries Foundation
Patricia and Stephen Paddock
Timothy Paisley
Palm Bay International, Inc.
The Pampered Chef
Chester Panek
Paramount Capital Group
Katharine and Bret Parker
Clint Parsons
Pat Boone Foundation, Inc.
Florence H. Pattee
Frances Paulsen
John and Gail Payne Charitable Gift Fund
Steven and Nancy Payne Fund
Amy and Brook Payner
John P. Peavy
Peerless Clothing International
Faye Pender
Sandra and Norman Pessin
Nancy Peterson
Susan Toenissoetter and Daniel Petree
Carrie and William Petty
PG Productions, LLC
Rosalind and Edward Pineles
Pittman Family Foundation
Pivot Architecture
The Plymouth Rock Foundation
Louise Poozer
Ann and Peter Pollack
Pond Jumpers
Elaine and Henry Pape Jr.
Carol A. Porter
Marc Porter
Poudre Valley Health System Foundation
Debbie, Rick, Ashley and Jeremy Powell
Philip Press
Anthony and Jeanne Pritzker Family Foundation
Tony Proctor
Dina and Douglas Propp
Gail Propp
Marc Puich
Mr. and Mrs. Thomas W. Purcell, Jr.
Teri and Randall Putnam
Kelli and Allen Questrom
Sandra and Darrel Quick
Stephen G. Quill
R.S. Quality Products, Inc.
Stewart Rahr
Lisa and Jim Ramsay
Karen L. Ramsey
Kathleen and C. Dean Rasmussen
Adam Ratica
Robert Rau
Raymond Benner Living Trust
Mary Reaske
Andrew and Monique Rechtschaffen
Angie and Steve Redding
Sharman Reecher
The Reichert Foundation
Kurt Reinsberg Philanthropic Fund
Barbara and Paul Retzin
Jack Remmet
Eileen Rencher
The RFP Fund, Inc.
Jill and Scott Rhea
Dave and Lori Rhodes
Irene Hegeman Richard, MD
Harry and Verna Richardson
Joseph Richter
Norman & Myrna Ricken Charitable Trust
Barbara and Craig Robbins
Virginia Robbins
Susan and Robert Roberts
Sandy and Mark Robinson
The Martin and Ellen Robinson Charitable Fund
Nicholas Roccanova
Laurie G. Rocha
Jack Rodin
Joan Rodrigues
Margaret and John Roeper
Larry Rogovin
Jullie and Garry Rolls Charitable Fund
Meg and John Rosecky
Alex Rosello
Scott Rosenburg
Eva Yarmo and David Rosenthal
Mitchell Rosenthal
Tibby and Abby Ross
The Rothfeld Family Foundation
Melissa and Matthew Rubel
Steven G. Rubenstein
Terry S. Newman and David B. Rubin Charitable Fund
Robert N. Rubin
Ellen Rudman
Senator Warren Rudman
The Brenner Rudman Charitable Trust
Rup nell Lee Family Foundation
Michelle and John P. Russo
David Sack
Leslie Sack
Stephen Sacks
Michael E. Sadres
Sage Software, Inc.
Elizabeth Doyle and David Saltzman
Troy and Connie Salyers
James and Janet Sammer
Maja Kietzke and Anthony Sanchez
Dave Sankey
Jack Savely
Kenneth Sawka
Linda Sawyer
Scars Into Stars Charity
Joshua Schechter
Schechter Foundation
Harry and Lila Schiffman
Suzette and Jay Schochet
Luci Schofield
The Jean and Thomas Schreiber Philanthropic Fund
Nina and Paul Schroder
Schulman Family Foundation
Judith and John Schumacher
Marc Schumann
Mark Schupack
Mary and Richard Schuster
Susan Schutzman
Teresa and Daniel Schwartz
Meryl and Jeff Schwartz
Walter A. Scott
Georgia L. Sebek
Raquel and Andrew Segal
The Selkowitz Family Foundation
Ambassador and Mrs. Mel Sembler
Karen and Samuel Seymour
Sara and Mark Shacket
Marjory and Jeffrey Sharp
Clifford A. Sheets
Marti M. Shell
Pauline and Alex Shender
Martin M. Shenkman Revocable Trust
Marilyn and Rex Sheppard
John H. Ship
Debbie and Steven Shough
Rose Betty Short
Judith M. Shutz
The Sidewater Family Foundation, Inc
Wendy and Stephen B. Siegel
Sierra Microwave Technology, LLC
Ben Sihota
Mr. and Mrs. Steven Silver
David Sims
Gale Single
Jane and Steve Sinton
Aaron Sirulnick
Sanford Sirulnick
Bridge Sisson
Paula and Charles Small
Derek Smith
Dione and Joseph Smith
Piper and Roger Smith
Samuel A. Smith
Sydell and Ira N. Smith
Kristin K. Snow
Jacob Solomon
Lisa, Jared, Jake, and Mitch Solomon
The Solomon Group
Scott F. Sonkin
Fritz Eric Sperling Jr.
Lyne and Eric Spillman
Justin Spitzer
Don Springer
Eric Sprunk
Simon Staniak
Dan Stark
Dennis and Janice Steindler
Drs. Susan and Robert Stephens
Adam Sticpewich
Dana and Andrew D. Stone
Jacquie L. Strauss
Marie Strehb
Jennifer and Chad Streit
JoAnna Strizic
Amelie Stroh
Eric Strom
Harvey and Susan Stromberg
Peggy Sturman
Marianne Sufrin
Gary Suttle
Georjean Swis
Anne and Alan Taetle
Kathy Taggares
Karen A. Tamburlin
Edward Taran Fund
Lynne Tarnopol
Nancy and James Taylor
Nancy and Mark Taylor
TCA Bannockburn, LLC
TD Bank
John Teeger
TEM-PACE, Inc.
Helen L. Temple
A. Thakrar
Cindy and Robert Theberge
Lisa Thenell
Third Horizon Foundation
Mary and Homer Thomas
Michael Thomason
Michael Thompson
Michele and William Thompson
Rose Thorne
Frank and Margaret Throssell Fund
Tikars
Gail Tomberg
Mamie Tompkins
Catherine Toomer
Jack and Berte Toppell Family Foundation
Bruce Tower
Allison Townsend
Jean M. Trainor
Traub-Brittan Family Foundation
Terry Tribolet
Tri-State Health Association
Incorporated
Sussana and John Trittschuh
Linda B. Trugman
Todd D. Turnidge
Jane and Wat Tyler
Lisa Tyson
Unifratti Of America, Incorporated
United Way of the Columbia-Willamette
Nancy and Chris Unrath
Victoria and Walter Van Den Burg
Sally Van Dyke
Loren K. Vanderslik
Vector Search Group
Nicole and Michael Vermut
Hope and John Van Beuren
Van Wagner Communications, LLC
The Peggy & Ellis Wachs Family Foundation
The Wagner Family Foundation
Valerie Wagner
Wakefern Food Corporation
The Morton & Lilian Waldfogel Charitable Foundation
Suzanne E. Walsh
Charlie Wancio
Mary and Jack Ward
William Warden
Theresa and Bradley Warnecke
Jason Warner
David And Phyllis Warrick Fund
Phyllis J. Warrick
Washington Trust Company
Gayle F. Wasserman
Wasson Family
Richard Weber
Wechter Financial Services, Inc.
Eliot and Beth Wegbreit
Sheila and Edward Weidenfeld
Julie and Peter Weil
Christine Kelly and Morton O. Weinress
Elaine and Melville Weiner
Eleanor and Norman Weiss
The Roberta and Allan Weissglass Foundation
The Adam J. Weisssman Foundation
Sharon and James Welty
Jane Wenner
Westlake Golf and Country Club
John R. Wherry
Grace and Glenn Whitecotton
Mary and Rick Whiting
Whitlock and Associates
Mary E. Whitzworth
James Wicker
Elisha Wiesel
Daniel Wilkins
Brett, Jack, Charlotte and Cricket Wilkinson
Donald E. Will
Dale Williams
Michelle and Zach Williams
Lynn Wilmas
Allen Wilson
Murray John Wilson
Pete Wilson
Daniel Wistran
Joel S. Wojnilower
Meredith Wolff
Wolters Kluwer Health
World-Wide Holdings, Inc. Fund
Robert D. Woztmann
Gerald Wright
Jennifer and David Wroan
Brooke and Brett Wyard
Jean Yee
Wanda and Charles Young
Peggy Katz and James Young
Mary Ellen and Jim Young
Fei and Wei Yu
Larry S. Zajdel
Loreen Zaken
Lois and Andrew Zaro
Craig Zinserling
Daina Zivarts
Denice and Tom Zucca
## 2009 Tributees

<table>
<thead>
<tr>
<th>Organizations</th>
</tr>
</thead>
</table>
| Individuals and individuals and in tribute have been made generously.

Donations have generously been made in tribute to the following individuals and organizations.

<table>
<thead>
<tr>
<th>2009 Tributees</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert D. Bruce</td>
</tr>
<tr>
<td>Robert Buchanan</td>
</tr>
<tr>
<td>Edward Burke</td>
</tr>
<tr>
<td>William O. Burnett</td>
</tr>
<tr>
<td>Jerry R. Burns</td>
</tr>
<tr>
<td>Barbara C. Calvert</td>
</tr>
<tr>
<td>Janice Campbell</td>
</tr>
<tr>
<td>Minnie Cantor</td>
</tr>
<tr>
<td>Ross M. Canty</td>
</tr>
<tr>
<td>George W. Carpenter</td>
</tr>
<tr>
<td>Robert M. Carriger</td>
</tr>
<tr>
<td>Patrick A. Caruso</td>
</tr>
<tr>
<td>Barbara Carver</td>
</tr>
<tr>
<td>Margaret W. Caullwine</td>
</tr>
<tr>
<td>Elizabeth V. Cavano</td>
</tr>
<tr>
<td>Vincent Celenza</td>
</tr>
<tr>
<td>David Cerrina</td>
</tr>
<tr>
<td>Josephine Cerrina</td>
</tr>
<tr>
<td>Joyce Chalnich</td>
</tr>
<tr>
<td>Chinghua P. Chang</td>
</tr>
<tr>
<td>Elizabeth A. Chase</td>
</tr>
<tr>
<td>Arthur A. Checchi</td>
</tr>
<tr>
<td>Wes Christie</td>
</tr>
<tr>
<td>Ronald T. Chung</td>
</tr>
<tr>
<td>Jeanne A. Clare</td>
</tr>
<tr>
<td>Patricia Clarke</td>
</tr>
<tr>
<td>John W. Coffey</td>
</tr>
<tr>
<td>Barry J. Cohen</td>
</tr>
<tr>
<td>Louis Cohen</td>
</tr>
<tr>
<td>Richard Cohen</td>
</tr>
<tr>
<td>Howard Cohan</td>
</tr>
<tr>
<td>Gerald F. Conlin</td>
</tr>
<tr>
<td>Joseph E. Connor</td>
</tr>
<tr>
<td>William Conroy</td>
</tr>
<tr>
<td>John B. Cooke</td>
</tr>
<tr>
<td>Hiram L. Cooley</td>
</tr>
<tr>
<td>Denise Costa</td>
</tr>
<tr>
<td>Lucien J. Cote</td>
</tr>
<tr>
<td>Robert Cowhey</td>
</tr>
<tr>
<td>Don Crisup</td>
</tr>
<tr>
<td>William C. Curtis</td>
</tr>
<tr>
<td>Limwood Custalow</td>
</tr>
<tr>
<td>Dad</td>
</tr>
<tr>
<td>Antoinette R. Dalo</td>
</tr>
<tr>
<td>Joseph A. D’Anna</td>
</tr>
<tr>
<td>Rex Davis</td>
</tr>
<tr>
<td>Susan M. Davis</td>
</tr>
<tr>
<td>Glenn Davis-Anacker</td>
</tr>
<tr>
<td>James N. De Haaff</td>
</tr>
<tr>
<td>Victoria Dean</td>
</tr>
<tr>
<td>Donald H. Delayes</td>
</tr>
<tr>
<td>Robert G. Deloury</td>
</tr>
<tr>
<td>Rocco J. Demilio</td>
</tr>
<tr>
<td>Lorraine DePompa</td>
</tr>
<tr>
<td>David F. DelWaters</td>
</tr>
<tr>
<td>Marina J. Dewey</td>
</tr>
<tr>
<td>John A. Dieken</td>
</tr>
<tr>
<td>Manuel V. Diez</td>
</tr>
<tr>
<td>Rudolph DiNunzio</td>
</tr>
<tr>
<td>Mary C. Docherty</td>
</tr>
<tr>
<td>Charles Doering</td>
</tr>
<tr>
<td>Alex Doolas</td>
</tr>
<tr>
<td>Roger Durban</td>
</tr>
<tr>
<td>William Dusterhout</td>
</tr>
<tr>
<td>Thomas D. Ebner</td>
</tr>
<tr>
<td>Lois A. Elander</td>
</tr>
<tr>
<td>Anne-Cecilie Engell Sprey</td>
</tr>
<tr>
<td>Thomas English</td>
</tr>
<tr>
<td>Morris L. Estess</td>
</tr>
<tr>
<td>Everyone at Rock Steady Boxing</td>
</tr>
<tr>
<td>Everyone with Parkinson’s Disease</td>
</tr>
<tr>
<td>Dorothy Evslin</td>
</tr>
<tr>
<td>Anne Eyes</td>
</tr>
<tr>
<td>Ralph P. Fader</td>
</tr>
<tr>
<td>Jack Famularo</td>
</tr>
<tr>
<td>Jeanne H. Faulkner</td>
</tr>
<tr>
<td>Natalie H. Fay</td>
</tr>
<tr>
<td>Albert L. Fierro</td>
</tr>
<tr>
<td>Karen L. Finerman</td>
</tr>
<tr>
<td>Emanuel Finkelstein</td>
</tr>
<tr>
<td>Patrick Finnegan</td>
</tr>
<tr>
<td>Richard H. Fitzgerald</td>
</tr>
<tr>
<td>Ronald H. Fitzsimmons</td>
</tr>
<tr>
<td>Earle R. Flesher</td>
</tr>
<tr>
<td>John L. Flowers</td>
</tr>
<tr>
<td>John J. Foley</td>
</tr>
<tr>
<td>Manuel Forman</td>
</tr>
<tr>
<td>Julian F. Forthofer</td>
</tr>
<tr>
<td>Lawrence E. Forthofer</td>
</tr>
<tr>
<td>Michael J. Fox</td>
</tr>
<tr>
<td>Charles Frantz</td>
</tr>
<tr>
<td>Theodore Fratzis</td>
</tr>
<tr>
<td>Helen Frustin</td>
</tr>
<tr>
<td>Daniel B. Frost</td>
</tr>
<tr>
<td>Cynthia Fucci</td>
</tr>
<tr>
<td>Richard Garber</td>
</tr>
<tr>
<td>Joseph A. Garraffa</td>
</tr>
<tr>
<td>Natalie Gasior</td>
</tr>
<tr>
<td>Abraham Gaslow</td>
</tr>
<tr>
<td>Paula Gaston</td>
</tr>
<tr>
<td>Patricia Gateff</td>
</tr>
<tr>
<td>Melvin Gerber</td>
</tr>
<tr>
<td>Joseph P. Gibbons</td>
</tr>
<tr>
<td>Jan Gibson</td>
</tr>
<tr>
<td>Joseph W. Gibson</td>
</tr>
<tr>
<td>Jack Gieskece</td>
</tr>
<tr>
<td>Bob Ginsberg</td>
</tr>
<tr>
<td>Albert B. Glickman</td>
</tr>
<tr>
<td>David Glickman</td>
</tr>
<tr>
<td>Judith Glickman</td>
</tr>
<tr>
<td>Sandra Gluck</td>
</tr>
<tr>
<td>Esther Goldberg</td>
</tr>
<tr>
<td>Sheldon Goldstein</td>
</tr>
<tr>
<td>Margot Gosen</td>
</tr>
<tr>
<td>David A. Graffam</td>
</tr>
<tr>
<td>Lafayette M. Gravely</td>
</tr>
<tr>
<td>Rhonda L. Greear</td>
</tr>
<tr>
<td>Dorothy Greene</td>
</tr>
<tr>
<td>Elliott S. Greenspan</td>
</tr>
<tr>
<td>Matthew Greenstein</td>
</tr>
<tr>
<td>Curtis L. Greenway</td>
</tr>
<tr>
<td>Rosa L. Griffin</td>
</tr>
<tr>
<td>Grace S. Griffith</td>
</tr>
<tr>
<td>Carl Grossman</td>
</tr>
<tr>
<td>Fred W. Grotphorst</td>
</tr>
<tr>
<td>William A. Gray</td>
</tr>
<tr>
<td>Paul Gustavson</td>
</tr>
<tr>
<td>Cindy Hadaway</td>
</tr>
<tr>
<td>John S. Hager</td>
</tr>
<tr>
<td>Sylvia Harman</td>
</tr>
<tr>
<td>Ramona A. Harmon</td>
</tr>
<tr>
<td>Kermit Harner</td>
</tr>
<tr>
<td>Stanley Hart</td>
</tr>
<tr>
<td>William J. Harte</td>
</tr>
<tr>
<td>William Hauf</td>
</tr>
<tr>
<td>Susan B. Haverstock</td>
</tr>
<tr>
<td>Leo E. Helderan</td>
</tr>
<tr>
<td>Jerome Helgren</td>
</tr>
<tr>
<td>Anita S. Henry</td>
</tr>
<tr>
<td>Patrick Henry</td>
</tr>
<tr>
<td>Dena Herema</td>
</tr>
<tr>
<td>Michelle Hespeler</td>
</tr>
<tr>
<td>Patricia C. Hester</td>
</tr>
<tr>
<td>Leonard F. Hill</td>
</tr>
<tr>
<td>Naomi Hoffman</td>
</tr>
<tr>
<td>Robert B. Holland</td>
</tr>
<tr>
<td>Jim Holt</td>
</tr>
<tr>
<td>Katie Hood</td>
</tr>
<tr>
<td>Richard E. Hoover</td>
</tr>
<tr>
<td>Sarah K. Horn</td>
</tr>
<tr>
<td>Warren Hottenstein</td>
</tr>
<tr>
<td>Doris J. Houser</td>
</tr>
<tr>
<td>Lo-Ching Hua</td>
</tr>
<tr>
<td>Bertha L. Humphrey</td>
</tr>
<tr>
<td>John R. Humphrey</td>
</tr>
<tr>
<td>William H. Hyde</td>
</tr>
<tr>
<td>Frances V. Ireland</td>
</tr>
<tr>
<td>Dave Iverson</td>
</tr>
<tr>
<td>Philip R. Jamison</td>
</tr>
<tr>
<td>Joseph S. Jankovic, MD</td>
</tr>
<tr>
<td>Alberto Jimenez</td>
</tr>
<tr>
<td>Charles L. Johnson</td>
</tr>
<tr>
<td>Gerald L. Johnson</td>
</tr>
<tr>
<td>Rhonda B. Johnson</td>
</tr>
<tr>
<td>Freeman P. Jordan</td>
</tr>
<tr>
<td>Julia Jordan</td>
</tr>
<tr>
<td>Mary Kamal</td>
</tr>
<tr>
<td>Delphine Kaminski</td>
</tr>
<tr>
<td>Amalia S. Kaminsky</td>
</tr>
<tr>
<td>John E. Kandel</td>
</tr>
<tr>
<td>Larry E. Kandel</td>
</tr>
<tr>
<td>Marshall A. Kaplan</td>
</tr>
<tr>
<td>Maurice Kaufman</td>
</tr>
<tr>
<td>Ernest Kellar</td>
</tr>
<tr>
<td>S. Arliss Kemp</td>
</tr>
<tr>
<td>Violet M. Kent</td>
</tr>
<tr>
<td>Clifford R. Kessler</td>
</tr>
<tr>
<td>John W. King</td>
</tr>
<tr>
<td>James C. Kirk</td>
</tr>
<tr>
<td>Mary L. Kissel</td>
</tr>
<tr>
<td>Mary L. Kissell</td>
</tr>
<tr>
<td>Eugenia Kog</td>
</tr>
<tr>
<td>Frank Kotch</td>
</tr>
<tr>
<td>Edward W. Kowalczyk</td>
</tr>
<tr>
<td>Selma I. Koznek</td>
</tr>
<tr>
<td>Barbara Kraly</td>
</tr>
<tr>
<td>Clyde L. Krogh</td>
</tr>
<tr>
<td>Robert Kroupa</td>
</tr>
<tr>
<td>Renee Kmetz</td>
</tr>
<tr>
<td>Gerald T. Kurtz</td>
</tr>
<tr>
<td>Bonnie Kutas</td>
</tr>
<tr>
<td>Dirk A. Kayk</td>
</tr>
<tr>
<td>John N. Lam</td>
</tr>
<tr>
<td>Bernard C. Lamas</td>
</tr>
<tr>
<td>Michelle D. Lane</td>
</tr>
<tr>
<td>Selma Lanes</td>
</tr>
<tr>
<td>Robert E. Larson</td>
</tr>
<tr>
<td>Elliott Latez</td>
</tr>
<tr>
<td>Robert F. Latimer</td>
</tr>
<tr>
<td>John J. Lauroe</td>
</tr>
<tr>
<td>Neil Laurin</td>
</tr>
<tr>
<td>David M. Laushey</td>
</tr>
</tbody>
</table>
Stephen Lawrence
Megan Layer
Sylvia M. Lazar
Wanda M. Leach
Merle Leake
Joy Leichenger
Roland H. Leisy
William B. Leonard
George Lerman
Martin Levin
H. Burton LeVine
Gustave L. Levinson
Arnold Levy
Edwin A. Levy
Linda Avey's Father
Ariel Linden
Arthur E. Lindroos
David F. Lindsay
Gerhard D. Linz
Jennifer Lipschultz
Marc S. Lipschultz
Val Livingston
Barbara Lizerbram
Richard Locke
Jim Long
Delores Lorenzo
Donald N. Lykens
John T. Lykouretzos
Fred Mann
Michael J. Manning
Elena Manno
Ellis L. Marks
Ralph H. Marquet
Robert Marvan
Harry Maunu
Marilyn H. Mayer
Teddy Mayer
Mitsuko McCandlish
Ida L. McClure
Sean McConnell
Cleo McCruden
Rosemarie McCrory
Kathy McCune
Thomas J. McCade
E. Janet McDonald
Edward McGah
Mary Etta McGaughy
Patrick T. McGowan
Carol R. McGuire
Louise McLaren
James D. McMahon
John J. McNamara
James W. McTague
Robert G. Meelheim
Richard L. Meinink
Mike Melzer
John C. Mendillo
Barry Mensch
Lavonne S. Mensing
Scott Meril
Cora Messinger
Joyce A. Metcalf
John R. Meyer
Patricia Michaels
David O. Miller
Leo Miller
Shirley Miller
Jewell O. Mohn
Jerry Moore
Monica Morekin-Serfas
Thomas P. Morrissey
Mary C. Murphy
Thomas P. Murphy
Wilma J. Murri
Donald J. Murtonen
Cheryuth Nath
Noel Nathanson
Susan Nathanson
Maurice R. Nazaren
Robert G. Neale
Ron Nelson
Joseph D. O'Brien
Catherine S. O'Connell
Mary L. Ostrowski
LaVonne Pagelow
Donald G. Paige
Mary A. Palmer
Muriel J. Parmenter
John Paron
Hillery A. Parrack
Robert W. Patin
Narhari Patolia
Joseph C. Patteee
James H. Patterson
Anne Paykos
David H. Peery
Claireanne Pell
Harold D. Pendergast
Robert E. Penny
Ruth Perrigino
Mary B. Perry
Norman H. Pessin
James J. Peters
Jim Peterson
Richard T. Peterson
Homer E. Plefferkorn
Raymond E. Pittman
Albert B. Polen
Stephen M. Pollan
Joel Portnoy
Jack M. Posen
Lane D. Powell
Joel Press
Dolores M. Princotta
Robert Pritzker
Charles H. Pulley
Sue B. Pye
Thomas B. Ramsey
Gary L. Randall
Richard Randall
Theodore M. Ratica
Kenneth A. Reecher
Kevin Reilly
Margaret M. Rhea
Roger J. Rice
Jacqueline Richard
Deborah Ridel
Antonio Rimanelli
Robert E. Roderick
Sona Rodin
Richard M. Rothenberg
George W. Rouke
Judith F. Rubin
Josef Ruppl
Helen Runnels
Alfred G. Russell
Kenneth B. Russell
Hans Salomon
Harry Salter
Jessie Santini
Edith Saunders
Shiv L. Sawhney
Giuseppe Scattone
Helmut M. Schaffler
Carolyn Schenker
Gail Schmerl
Richard L. Schneider
Thomas M. Schroeder
Margaret M. Schuman
Elaine W. Schuster
Frank G. Sebek
Delores A. Seebor
Jerome A. Sertick
Robert W. Shackleton
Paul R. Shalita
Ruby Shepherd
Jerome P. Shifter
Yoko Shintani
Joanne Ship
Debbie Shough
Georgina Silva
Evelyn Simon
Melvin Simon
Alexander M. Sinclair
Merle E. Singer
Frederick J. Sisson
Mary E. Skewes
Charles Sklar
Leo J. Sklar
Patricia A. Sloan
Edward Smallwood
Clare D. Smith
Guy H. Smith
Hugh P. Smith
Ira N. Smith
Princie L. Smith
Sandra M. Smith
Martha Snow
Mary L. Solema
Judith C. Spencer
Emily Spiegel
Jerry Spiegel
Ann K. Spier
Jack Spillman
Warren E. Sprague
David Steen
Riya Steinman
David Steen
Warren E. Sprague
David Steen
Ray Steinman
Susan A. Stephens
Donald J. Stewart
Harry J. Stingley
Stanko S. Stojkovic
Howard M. Strauss
Mary G. Strazz
Edward A. Strebel
Robert F. Streit
Joseph J. Strizic
Shirley Stroud
Eva Stuenkel
Arnold L. Sutta
Craig Swanson
Paul Swanson
Robert O. Sykes
Robert Temple
Colburn R. Thomsan
Andrew Tobias
Jack Toppell
William Torresi
Judith A. Towler
Jennifer Trittschu-Valles
John R. Twiss
Miller H. Ullmann
Martin B. Unger
Alvin Vanderslik
James Vaugh
Virginia Norris's Mother
Thomas A. Wagner
Irene Wakabayashi-Yanaga
Sharon Walker
Anthony W. Walsh
Antoinette Warden
Stephen D. Weinrress
Leona Welty
Stephen Welty
Annette Westerman
Bill J. Whitworth
Richard J. Wiedner
Earl Wiener
Jack Wilco
Samuel A. Wilkinson
David R. Williams
Linda Williams
John S. Wilson
Elisie Winn
William H. Winston
Mildred Wise
Sue Wojnilower
Marly Wolff
Dorothy M. Yares
Barbara P. Young
Charles W. Young
Miriam Zaretzsky
Marla Zivarts
Iva V. Zucca
Seymour Zwerin
In 2009, over 1,000 dedicated Team Fox members collectively raised nearly $3 million to support The Michael J. Fox Foundation’s high-impact research programs. Whether they flip pancakes, start a golf tournament, hold a yard sale or run a marathon, these passionate and creative people all over the world form an unstoppable team that keeps finding more ways to help advance the Foundation’s vital work — bringing us all closer to new treatments and a cure for Parkinson’s disease.
ING NYC Marathon

Team Fox’s growing marathon program was honored to be included again as an official charity partner in the 2009 ING NYC Marathon. 220 runners from four countries and 21 U.S. states put one foot in front of the other for 26.2 miles to raise over $857,000 for The Michael J. Fox Foundation’s research toward a cure.
Patrick Hatton  
Chicago Marathon

Lori Hes  
More Marathon

Jeffrey Joseph  
Fireworks for Fox

Natalie Karp  
Canyon Ranch Group Trips

Mount Allison University  
Pancakes for Parkinson’s

Jillian Libenson  
1st Annual Nona Libenson 5K/10K

Linda Lyle  
Pay Forward for Parkinson’s

Chaya Mallavaram  
Memorial Gifts

Jason Matter  
Triple Bypass Bike Ride

Jill Matter  
Triple Bypass Bike Ride

Dustin Matthews  
Hacker’s Cup Golf Tournament

Robin Maxcy  
Boston Marathon

Clent Mericle  
Hit the Road Jack 5K Run/Walk

Amy Miller  
Twin Cities Marathon

The Monusky Family  
2009 “60 for 60” Campaign for Parkinson’s Disease Research

Kevin Moss  
South Florida Team Fox Scuba Dive

Rosemary Pepe  
Party to End Parkinson’s

Jennifer Porter  
Popcorn for Parkinson’s

Colette Porcelli Lettieri  
Inn at Quogue Fashion Show

Kim Ready  
Cowtown Ultra Marathon

Samuel Ross  
Marine Corps Marathon

Running for Papa  
Nashville Country Music Marathon

Lori Saviers  
10 Mountains 10 Years: A Quest for the Cure

Trey Sebus  
Chicago Marathon

Steve Spencer  
“You Can’t Take It With You” Play Proceeds

Brian Thorne  
2nd Annual Friends of Team Fox Holiday Party

Kari Travis  
Boston Marathon

Colleen Wuebben  
Wuebben Family Skate-a-Thon

$1,000 or more

Maureen Ashdown  
Pocket Change 4 Parkinson's

Berkeley County Parkinson's Support Group  
Bonanza and Softball Tournament

Richard Broughton  
The Annual OBX CruZ for the Cure of Parkinson’s Disease

Jessica Brown  
Capital of Texas Triathlon

Sarah Bunn  
“Detoxify Your Life” Seminar

Lou Bushinsky  
Chicago Marathon

Graine Byrne  
NYC Half Marathon

Bonnie Chi  
NYC Half Marathon

Vicky Clark  
Sale for a Cure

Ken Clary  
WhistleStop Marathon

Jennifer Cogan  
Philadelphia Marathon

Eileen Colon  
The Army of Change

Katie Congdon  
Willow Tree Half Marathon

John Cuccinello  
Jarden Westchester Triathlon

Laura Dalle Pazze  
Warrior Dash

Stella Darby  
Liversedge Half Marathon

Jeffrey Davis  
Team Fox Athlete

Michelle De Luca  
NYC Half Marathon

Robert Denlow  
Boston Marathon

Meghann Dials  
Illinois Marathon

The Dobrez Family  
Team Fox Fundraiser

Greg Drumheller  
The Jerry G. Barnhart Memorial Poker Tournament

Marlin Eldred  
Humpy’s Classic Marathon

Elaine Ellis  
Premier Jewelry Show

Inci Ertan  
Dinner & Cooking Class

Ian Fagan  
NYC Half Marathon

Brandy Fain Netzer  
ING Half Marathon

Dani Farber  
NYC Half Marathon

Miranda Feldmann  
Silly Spooky Movie Nights

Christine Finn  
NYC Half Marathon

Morgan Fixel  
Team Fox Fundraiser

Hailey Flynn and Robin Lee  
NYC Half Marathon

Linda Foresha  
Pirouettes for Parkinson’s

Sheldon Garfinkle  
NYC Half Marathon

Helen Gery  
Purse Sales

Alan Gettis  
Philadelphia Marathon

Mark Gherty  
American Birkebeiner

Jacqueline Gibbons  
Hartford Half Marathon

Jill Goldenzien  
Boston Half Marathon

Eugene Gurkoff  
Team Fox Fundraiser

Sandra Haas  
NYC Half Marathon

Helen Hugg  
Purse Sales

Adam Hegge  
Pull for Parkinson’s

Chad Henson  
Dallas White Rock Marathon

Kieran Hughes  
Special Occasion Gifts

Larry Ice  
Parkinson’s Awareness Building Events

Lenore Imhof  
Jarden Westchester Triathlon

Jordan Isenstadt  
NYC Half Marathon

Karen Janos  
Team Fox Fundraiser

Lisa Jay  
Spectrum Fall Dance

Jennifer Johns  
Boston Marathon

Tara Jay Johnson  
The Richard L. Johnson Memorial Golf Tournament

Brad Kear  
Multiple Marathons

Mary Kelly  
Team Fox Athlete

James Knuckles  
Chicago Marathon

Jeffrey LaGrange  
Board of Education

Dress Down Day

Tracy Lehnecker  
Medicus Foundation Fundraising

Brian Levy  
NYC Half Marathon

Michael Lewis  
Honor Gifts

Peter Liberto  
Friends Helping Friends

Jennifer Love  
Pancakes for Parkinson’s

Nate Lukas  
More than Words: A Benefit Concert

Madison Lyleohr  
Vocal Performances and CD Proceeds

Edward Macdonald and Nikita Romanoff  
NYC Half Marathon

Chris Magoon and Katie Magoon  
Providence Rhode Race

Lisa and Branko Maric  
Joint Birthday Party

Theresa Marran  
Team Fox Dessert Buffet

Mark Mason  
Kona Ironman

Cassandra Matrianni  
Pizza for Parkinson’s and Day of Enchantment

Soania Mathur  
Team Fox Fundraiser

Sean McDonald  
Cedar Springs Circle Annual Crawfish Boil

Sasha Mobley  
Healdsburg Half Marathon

Amanda Neal  
Tour of Anchorage

(continued from page 37)
2009 Community Fundraisers

The Foundation is grateful to the following donors for their generous efforts to raise funds and awareness for MJFF and Parkinson’s research through community fundraising events.

$25,000 or more
23andMe
Michael Cotoia

$10,000 or more
itsource technology
Sydney Goldstein

$5,000 or more
all tri, inc.
Chris Piper

$2,500 or more
Robert Benjamin/Light of Day Foundation
California Jurisdictional Convention
Illinois Shotokan Booster Club
JTB International Ltd.
Megan Layer
Rocking For Parkinson’s Disease Research Foundation, Inc.
Brad Schenker Bar Mitzvah
Sandy Smith

$1,000 or more
Aeroquip Credit Union
Judith Binder
Karen deGraaf
Stephen E. Farris
Federal Aviation Administration
Mark Friedman
Ariel Linden
Hamden High School Hockey Alumni Association
I Do Foundation
Micanopy Area Chamber of Commerce
MissionFish
Eileen O’Neill
Scars Into Stars Charity
Anne-Cecilie Engell Speyer and Rob Speyer
Tokio Marine Management, Inc.
Wells Fargo Community Support Campaign
Westlake Golf and Country Club
The Michael J. Fox Foundation believes donors have a right to look for measurable returns on their investment. We operate according to best practices and remain accountable to our donors and the Parkinson’s community for ensuring maximum effectiveness. Our leadership was recruited from the worlds of finance, management and neuroscience, bringing strategic skills, scientific and operational expertise, and an investment professional’s sensibility to the management of the Foundation.

- We constantly monitor costs to maximize the value of donations. Since inception, 86 cents of every dollar we’ve spent has gone straight to our research programs effort.

- We are outcomes-focused, tying grant payments to the achievement of specific milestones, troubleshooting challenges if
they arise, and halting funding if the science stalls. And we demand the same accountability and transparency of ourselves as we do of our awardees.

We deliberately have no endowment, because we believe that to speed a cure for Parkinson’s disease, our capital needs to get into scientists’ hands as quickly as possible — not sit in an endowment or reserve.

MJFF ended 2009 closing in on the $200-million mark in research funded since inception. Ultimately, though, we measure our impact not in terms of dollars spent, but in terms of scientific solutions that produce tangible improvements in patients’ lives.

2009 financial highlights follow. Full audited financials and our most recent IRS Form 990s are available at michaeljfox.org.

“Donors to The Michael J. Fox Foundation for Parkinson’s Research have provided funds used to expedite grant processes, establish benchmarks for progress, apply continuous evaluation practices, and invest in a portfolio of promising research initiatives simultaneously... helping to reduce the overall risk of research investments, create new incentives for scientists and change the culture and expectations around medical research.”

Issue Brief: Investing in Medical Research, Arabella Philanthropic Investment Advisors (2010)
### Consolidated Statements of Financial Position

**As of December 31,**

<table>
<thead>
<tr>
<th></th>
<th>2009</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash, cash equivalents and investments</td>
<td>$33,422,684</td>
<td>$30,962,536</td>
</tr>
<tr>
<td>Contributions receivable, net</td>
<td>35,401,415</td>
<td>26,762,424</td>
</tr>
<tr>
<td>Prepaid expenses and other current assets</td>
<td>156,687</td>
<td>162,958</td>
</tr>
<tr>
<td>Security deposits</td>
<td>33,061</td>
<td>33,061</td>
</tr>
<tr>
<td>Inventory</td>
<td>28,036</td>
<td></td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>278,893</td>
<td>388,610</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>$69,320,776</td>
<td>$58,309,589</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2009</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Liabilities and Net Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$1,713,780</td>
<td>$1,066,594</td>
</tr>
<tr>
<td>Grants payable, net</td>
<td>42,161,174</td>
<td>38,882,706</td>
</tr>
<tr>
<td>Loan payable</td>
<td>1,000,196</td>
<td>1,000,196</td>
</tr>
<tr>
<td>Interest payable</td>
<td>59,511</td>
<td>13,089</td>
</tr>
<tr>
<td>Deferred rent</td>
<td>358,114</td>
<td>367,192</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td>45,292,775</td>
<td>41,329,777</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2009</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net Assets:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted</td>
<td>2,345,986</td>
<td>(5,516,236)</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>21,682,015</td>
<td>22,496,048</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td>24,028,001</td>
<td>16,979,812</td>
</tr>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td>$69,320,776</td>
<td>$53,309,589</td>
</tr>
</tbody>
</table>

*Note: Investments are highly liquid.*
Consolidated Statements of Activities

<table>
<thead>
<tr>
<th>Year Ended December 31,</th>
<th>2009</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Public support and revenue:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions</td>
<td>$ 45,433,897</td>
<td>$ 35,335,877</td>
</tr>
<tr>
<td>Special events</td>
<td>5,825,680</td>
<td>6,741,990</td>
</tr>
<tr>
<td>Investment income</td>
<td>119,440</td>
<td>662,655</td>
</tr>
<tr>
<td>Miscellaneous income</td>
<td>37,425</td>
<td>25,682</td>
</tr>
<tr>
<td><strong>Total public support and revenue</strong></td>
<td>51,416,442</td>
<td>42,766,204</td>
</tr>
<tr>
<td><strong>Expenses:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program services</td>
<td>39,153,137</td>
<td>36,236,785</td>
</tr>
<tr>
<td>Management and general</td>
<td>1,263,737</td>
<td>1,093,996</td>
</tr>
<tr>
<td>Fund-raising</td>
<td>3,951,379</td>
<td>4,130,806</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td>44,368,253</td>
<td>41,461,587</td>
</tr>
<tr>
<td><strong>Change in net assets</strong></td>
<td>7,048,189</td>
<td>1,304,617</td>
</tr>
<tr>
<td>Net assets, beginning of year</td>
<td>16,979,812</td>
<td>15,675,195</td>
</tr>
<tr>
<td><strong>Net assets, end of year</strong></td>
<td>$ 24,028,001</td>
<td>$ 16,979,812</td>
</tr>
</tbody>
</table>

The Michael J. Fox Foundation for Parkinson’s Research

Consolidated Statements of Activities

<table>
<thead>
<tr>
<th>Year Ended December 31,</th>
<th>2009</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Public support and revenue:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions</td>
<td>$ 45,433,897</td>
<td>$ 35,335,877</td>
</tr>
<tr>
<td>Special events</td>
<td>5,825,680</td>
<td>6,741,990</td>
</tr>
<tr>
<td>Investment income</td>
<td>119,440</td>
<td>662,655</td>
</tr>
<tr>
<td>Miscellaneous income</td>
<td>37,425</td>
<td>25,682</td>
</tr>
<tr>
<td><strong>Total public support and revenue</strong></td>
<td>51,416,442</td>
<td>42,766,204</td>
</tr>
<tr>
<td><strong>Expenses:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program services</td>
<td>39,153,137</td>
<td>36,236,785</td>
</tr>
<tr>
<td>Management and general</td>
<td>1,263,737</td>
<td>1,093,996</td>
</tr>
<tr>
<td>Fund-raising</td>
<td>3,951,379</td>
<td>4,130,806</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td>44,368,253</td>
<td>41,461,587</td>
</tr>
<tr>
<td><strong>Change in net assets</strong></td>
<td>7,048,189</td>
<td>1,304,617</td>
</tr>
<tr>
<td>Net assets, beginning of year</td>
<td>16,979,812</td>
<td>15,675,195</td>
</tr>
<tr>
<td><strong>Net assets, end of year</strong></td>
<td>$ 24,028,001</td>
<td>$ 16,979,812</td>
</tr>
</tbody>
</table>

The Michael J. Fox Foundation for Parkinson’s Research

Consolidated Statements of Activities

<table>
<thead>
<tr>
<th>Year Ended December 31,</th>
<th>2009</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Public support and revenue:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions</td>
<td>$ 45,433,897</td>
<td>$ 35,335,877</td>
</tr>
<tr>
<td>Special events</td>
<td>5,825,680</td>
<td>6,741,990</td>
</tr>
<tr>
<td>Investment income</td>
<td>119,440</td>
<td>662,655</td>
</tr>
<tr>
<td>Miscellaneous income</td>
<td>37,425</td>
<td>25,682</td>
</tr>
<tr>
<td><strong>Total public support and revenue</strong></td>
<td>51,416,442</td>
<td>42,766,204</td>
</tr>
<tr>
<td><strong>Expenses:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program services</td>
<td>39,153,137</td>
<td>36,236,785</td>
</tr>
<tr>
<td>Management and general</td>
<td>1,263,737</td>
<td>1,093,996</td>
</tr>
<tr>
<td>Fund-raising</td>
<td>3,951,379</td>
<td>4,130,806</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td>44,368,253</td>
<td>41,461,587</td>
</tr>
<tr>
<td><strong>Change in net assets</strong></td>
<td>7,048,189</td>
<td>1,304,617</td>
</tr>
<tr>
<td>Net assets, beginning of year</td>
<td>16,979,812</td>
<td>15,675,195</td>
</tr>
<tr>
<td><strong>Net assets, end of year</strong></td>
<td>$ 24,028,001</td>
<td>$ 16,979,812</td>
</tr>
</tbody>
</table>
Progress:
The 2009 Annual Report of The Michael J. Fox Foundation for Parkinson’s Research was published in June 2010. It is available in PDF format at www.michaeljfox.org.

Katie Hood
CEO
Michael J. Fox
Founder
Deborah W. Brooks
Co-Founder

Editor:
Holly Barkhymer
Associate Director, Communications

Writers:
Holly Barkhymer
Katrina Kahl
Associate Director, Communications

Designer:
Susan Shaw

The Michael J. Fox Foundation is a 501(c)3 nonprofit organization.
© 2010 The Michael J. Fox Foundation for Parkinson’s Research

Photo and Illustration Credits

On the cover
Dopamine neurons and their death in Parkinson’s disease. At left and center, cell death in the substantia nigra, the brain region affected in PD. At right, a dopamine neuron expressing LRRK2. LRRK2 mutations are now believed to be the most common genetic contribution to PD. Images courtesy of Robert Burke, PhD, Columbia University (left and center) and Mark Cookson, PhD, National Institute of Aging, National Institutes of Health (right).

Page 3
Photo of Katie Hood: Getty Images/Michael Buckner.
Photos of Michael J. Fox and Debi Brooks: Wireimage/Kevin Perry.

Page 4
Pre-clinical model cerebellum copyright 2002–2007, The Regents of the University of California. All Rights Reserved. Permission to use, copy, modify, and distribute any part of the Cell Centered Database (CCDB) website for educational, research, and non-profit purposes, without fee, and without a written agreement is hereby granted, provided that the above copyright notice, this paragraph, and the following three paragraphs appear in all copies.

Those desiring to incorporate this CCDB website into commercial products or use for commercial purposes should contact Dr. Maryann Martone at 858-822-0745 and Technology Transfer and Intellectual Property Services, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92039-0910, Phone: (857) 534-5815, Fax: (858) 534-7345, email: invent@ucsd.edu.

In no event shall the University of California be liable to any party for direct, indirect, special, incidental, or consequential damages, including lost profits, arising out of the use of this CCDB website, even if the University of California has been advised of the possibility of such damage.

The CCDB website provided herein is on an “as is” basis, and the University of California has no obligation to provide maintenance, support, updates, enhancements, or modifications. The University of California makes no representations and extends no warranties of any kind, either implied or express, including, but not limited to, the implied warranties of merchantability or fitness for a particular purpose, or that the use of the CCDB website will not infringe any patent, trademark, or other rights.

Page 5
LRRK2 images courtesy of Mark Cookson.

Page 6
Dopamine neuron images courtesy of John Sinclair.

Pages 8–9
Dopamine schematic courtesy of Dr. Paul Greengard, The Rockefeller University, with the technical assistance of Elisabeth Griggs.

Photo courtesy of Vanderbilt Medical Center.

Crystal structure of G-CSF as published in the Protein Data Bank (PDB: 1RHG), public domain. Created from PDB 1RHG and rendered by Ramin Herati using Pymol, March 10, 2007.

Pages 10–11
Photo of Marina Emborg courtesy of the University of Wisconsin, Madison.
Photo of Wolfgang Oertel courtesy of Philips University Marburg, Germany.

Photo of nicotine patch: Getty Images.

Pages 12–13
Photo of Angela Cenci-Nilsson courtesy of Lund University, Sweden.

Table depicts data produced in the laboratory of M.A. Cenci at Lund University, Sweden.


Page 14
Photo of Simon Lewis courtesy of the University of Sydney, Australia.

Pages 16–17
Zinc Finger Nuclease schematic courtesy of Sigma-Aldrich.

Photo courtesy of Weill Cornell Medical College.

Pages 20–21
Photos 1, 2, 5, 8, 14: Wireimage/Kevin Mazur.
Photos 3, 9, 12, 17: Ann Billingsley.
Photo 4 courtesy of Amar Kuchinad.
Photo 6 courtesy of Drew and Kyle Shackleton.
Photos 7, 11, 13: Getty Images/Michael Buckner.
Photo 10: Tommy Sandler
Photo 16: Elena Olivo.

Page 40
Elena Olivo.

Page 43
Elena Olivo.

Inside back cover
Yeast cells expressing human alpha-synuclein tagged with a green-fluorescent protein courtesy of Susan Lindquist, Whitehead Institute for Biomedical Research/Aaron Gitler, University of Pennsylvania.

The Michael J. Fox Foundation gratefully acknowledges Bulkley Dunton for donating the high-quality McCoy Silk Cover and Text paper on which this annual report was printed, and Yes Press for printing this report below cost.

Our gratitude to Hearst Corporation for facilitating both donations.
Board of Directors

George E. Prescott
Chairman

David Golub
Vice Chairman

Holly S. Andersen, MD
Eva Andersson-Dubin, MD
Jon Brooks
Barry J. Cohen
Donny Deutsch
David Einhorn
Karen Finerman
Nelle Fortenberry
Michael J. Fox
Albert B. Glickman
Mark L. Hart III
Skip Irving
Kathleen Kennedy
Morton M. Kondracke
Edwin A. Levy
Marc S. Lipschultz
Kenneth Olden, PhD, ScD
Douglas I. Ostrover
Tracy Pollan
Ryan Reynolds
Frederick E. Rowe
Lily Safra
Curtis Schenker
Woody Shackleton
Fred G. Weiss

Founders’ Council

Lonnie and Muhammad Ali
Steven A. Cohen
John A. Griffin
Andrew S. Grove
Jeffrey Katzenberg
Nora McAniff
Donna E. Shalala, PhD

Leadership Council

Scott Schefrin
Chairman

Claire Capello
Dev Chodry
Sonya Chodry
Anne-Cecilie Engell Speyer
Richard Fitzgerald
Lee Fixel
Sean Goodrich
Amar Kuchinad
Joella Lykouretzos

Patient Council

Eugenia Brin
Carey Christensen
David Eger, PhD
David Iverson
Soania Mathur, BSc, MD, CCFP
Thomas A. Picone, PhD
Richard Rothenberg
W.N. “Bill” Wilkins

Scientific Advisory Board

Gene Johnson, PhD
Chief Scientific Advisor*

Irene Hegeman Richard, MD
Senior Medical Advisor*

Alberto Ascherio, MD, DrPH
Erwan Bezard, PhD
Anders Björklund, MD, PhD
Susan Bressman, MD*
Robert E. Burke, MD
Angela Cenci-Nilsson, MD, PhD
Marie-Françoise Chesselet, MD, PhD
P. Jeffrey Conn, PhD
Mark Cookson, PhD*
David Eidelberg, MD
Matthew Farrer, PhD
Charles (Chip) Gerfen, PhD
J. Timothy Greenamyre, MD, PhD
Franz F. Hefti, PhD
Etienne C. Hirsch, PhD
Ole Hornykiewicz, MD
Ole Isacson, MD (Dr Med Sci)
Joseph Jankovic, MD*
Jennifer Johnston, PhD
Jeffrey H. Kordower, PhD
J. William Langston, MD
Frans Olof (Olle) Lindvall, MD, PhD
Andres Lozano, MD, PhD
Kenneth Marek, MD
Eldad Melamed, MD
Kalpana Merchant, PhD
C. Warren Olanow, MD
Bernard M. Ravina, MD, MSCE
Peter H. Reinhart, PhD
Ira Shoulson, MD
Andrew Singleton, PhD *
David G. Standaert, MD, PhD
Dennis A. Steindler, PhD
Caroline Tanner, MD, PhD
David Weiner, MD*
Michael Zigmond, PhD

* Executive Committee